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ABSTRACT OF THE DISSERTATION 
 
Vascular Protective Effects of Netrin-1  
and Netrin-1 Pre-conditioned Endothelial Progenitor Cells 
 
by 
 
Meng-Chia Liu 
Doctor of Philosophy in Molecular Cellular and Integrative Physiology 
University of California, Los Angeles, 2018 
Professor Hua Cai, Chair 
 
Many of the pathophysiological processes of vascular disease are attributed to 
endothelial dysfunction. Under normal conditions, nitric oxide (NO•) produced by endothelial 
NO• synthase (eNOS) plays a major role in maintaining vascular homeostasis. Due to a 
damage on endothelial cells (ECs), smooth muscle cells (SMCs) are proliferated and 
migrated to form neointimal cusion that can occlude blood vessels due to reduced NO• 
bioavailability. Platelets are also aggregated and activated to promote extracellular matrix 
production as well as additional inflammatory responses in the environment of disturbed NO• 
production. Therefore, one of the most effective approaches to protect the vasculature from 
these pathological circumstances would be to improve endothelial function. Cell-based 
therapies, such as approaches utilizing endothelial progenitor cells (EPCs), aim at 
accelerating revascularization. However, the challenge in cell isolation and acquisition of 
  iii 
sufficient cell number of EPCs from circulation has limited its clinical application. 
Nonetheless, our studies have demonstrated pre-conditioning of EPCs with netrin-1 can 
markedly improve their functions as to improved proliferative activity and survival capacity, 
and that with this treatment much less number of EPCs is sufficient to induce robust vascular 
protection when delivered in vivo. 
In our previous study, we demonstrated that NO• mediates mitogenic effects of 
netrin-1 on ECs via activation of DCC/ERK1/2 axis. The current study for the first time 
further revealed promoted functions of EPCs by netrin-1, which is also dependent on DCC 
and NO• production, resulting in protection against vascular endothelial damage. For these 
studies we employed two animal models; femoral artery wire injury model and apoE 
knockout mice fed high fat diet, for the development of neointima and atherosclerosis 
respectively. In addition to demonstration that netrin-1 protein infusion itself is robustly 
protective in these models, delivery of netrin-1 pre-conditioned EPCs proved to be markedly 
beneficial via augmented proliferation and resistance to oxidative stress. Moreover, the 
signaling pathway of NO•/cGMP/p38 MAPK was identified to mediate netrin-1 inhibition of 
SMC migration. The inhibitory effect of netrin-1 on monocytes adhesion to EC through 
UNC5B is also involved in the protection against atherogenesis. Although further studies are 
  iv 
required, the present study indicates the strong potential of netrin-1 and netrin-1 
pre-conditioned EPCs in vascular protection. 
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1. Introduction 
 
1-1. Endothelial Dysfunction in Cardiovascular Diseases 
 Endothelial cells (ECs) tightly connect to adjacent cells and form a single layer to 
cover the inner surface of vasculature in the entire body. They are making the first contact to 
circulating blood for vessels to regulate their homeostasis (Summarized in Figure 1-1). The 
ECs play a crucial role in controlling vascular tone, permeability, attraction of blood cells 
including lymphocytes that exhibit immunity, and proliferation/migration of underlying cells 
such as pericytes and smooth muscle cells (SMCs). Of note, nitric oxide (NO
•
) that generated 
from ECs has been long believed to play the central role in maintaining vascular homeostasis. 
Therefore, endothelial dysfunction initiates vascular occlusion via proliferation of SMC and 
accumulation of extracellular matrix, as well as recruitment of lymphocytes. Moreover, 
dysfunctional ECs retain oxidized lipoprotein in the subendothelial space. This further 
activates ECs and recruits monocytes which differentiate into macrophages and further 
mediate the formation of foam cells. Once foam cells are formed, there would be even more 
recruitment of inflammatory cells and malignant type of lipoprotein modification and thus 
build up lesions rapidly. These events are major components of atherogenesis, which 
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represents an inflamed state of artery. While normal ECs construct a barrier, which integrity 
is maintained via production of NO
•
 that reduces cellular oxidative stress [1]. Major 
cardiovascular risk factors such as aging, smoking, hypertension, hypercholesterolemia and 
hyperglycemia are known to alter endothelial physiology that leads to endothelial dysfunction. 
Importantly, in the presence of these cardiovascular risk factors, reactive oxygen species 
(ROS) degrade NO
• 
rapidly and alter the normal function of ECs, consequently leading to 
pathophysiological responses. Hence, repairing abnormality in EC physiology has a great 
potential to stop the progression of cardiovascular diseases. It is also important to develop 
methods to assess EC pathophysiology for early diagnosis, which can be utilized to minimize 
adverse events later in patients.
 3 
Figure 1-1. 
 
 
Figure 1-1. A central role of endothelial cells in regulating vascular homeostasis. The 
lining of healthy ECs constantly produce NO
•
, which inhibits platelet and monocyte 
recruitment as well as SMC migration and proliferation, thus maintaining vascular relaxation. 
Damaged ECs are shown in dark blue. When endothelium is dysfunctional, there is a 
reduction in NO
•
 bioavailability often consequent to an increased production of ROS, which 
leads to platelet aggregation or leukocyte adhesion to the intima. Cytokines produced from 
lymphocytes induce growth factor production and cause SMC hyperplasia and contraction. 
Monocyte recruitment due to reduced NO
•
 bioavailability leads foam cell formation in the 
subendothelial domain and triggers more inflammatory responses.  
This figure is modified from N Liu et at. Chapter 10, InTech (2017)  
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1-2. Nitric Oxide and Oxidative Stress in Endothelial Cells 
Disturbed production and reduced bioavailability of NO
• 
are major features of 
endothelial dysfunction. NO
•
 is generated from the amino acid L-arginine via activation of 
the enzyme endothelial NO synthase (eNOS), in the presence of other co-factors such as 
nicotinamide-adenine-dinucleotide phos-phate (NADPH) and tetrahydrobiopterin (BH4) [2]. 
Although NO
•
 has a short half-life approximately up to 6 to 30 second s[3], it is continuously 
synthesized in ECs and diffuses to adjacent cells. When NO
•
 is reached into SMCs, 
proliferation and migration are inhibited by activating soluble guanylyl cyclase (sGC) and 
sGC consequently produces cyclic guanosine monophosphate (cGMP). This is the most 
well-established pathway of NO
•
 regulating vasodilatation. ENOS mutant mice display 
hypertensive phenotype [4]. Activation of NO
•
-sGC-cGMP pathway also prevents platelet 
activation and its aggregation to endothelium. Recent studies have shown that platelets 
facilitates interactions between endothelium and inflammatory cells including monocytes, 
neutrophils and lymphocytes, largely via P-selectin[5]. Therefore, the inhibition of platelet 
aggregation by NO
•
 protects the blood vessels from inflammatory insults (Summarized in 
Figure 1-2). 
A great deal of angiogenic signaling pathways via NO
• 
produced from eNOS have 
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been reported. The proliferation, migration and anti-apoptosis effects on ECs are mediated by 
sGC/cGMP pathway, as well as s-nitrosylation, a post-translational modification adding 
nitrogen monoxide group [6]. Various mitogen activated protein kinases (MAPKs), such as 
ERK, MEK and AKT, are activated by NO. NO
•
 also can induce expression of endogenous 
angiogenic factors, often represented by vascular endothelial growth factor (VEGF).  
Therefore, at least in the context of pro-angiogenesis which is involved in the repair 
of ischemic diseases and wound healing, NO
•
, especially produced by eNOS in EC, is 
beneficial. However, there are some circumstances in which NO
•
 can be harmful. An 
inducible isoform of NOS, iNOS, is usually induced by inflammatory cytokines and/or ROS, 
and generates NO
•
 100 to 1000 times more than eNOS does [7]. Such high concentration of 
NO
•
 produced by iNOS induction promotes DNA damage and drives vascular cells apoptotic. 
In tumor angiogenesis, iNOS is more dominant than other isotype of NOS. As the tumor 
progress its malignancy, iNOS induce apoptosis in normal cells and acquisition of resistance 
to apoptosis in tumor cells by clonal selection of adaptation [6]. 
Thus, maintaining NO
•
 bioavailability in harmony is indispensable for a healthy 
vasculature. The definition of a healthy vasculature is being supple, with no excessive intimal 
cushion and blood or inflammatory cell aggregation. To accomplish it, activating eNOS to 
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produce more NO
•
, as well as inhibiting oxidative stress, such as by preventing eNOS 
uncoupling, would be necessary. The dysfunctional EC should be replaced to a functioning 
EC, in a physiological manner. Resident adjacent ECs can contribute to replace the damaged 
EC by their proliferation. The breakdown of cell-cell junctions between damaged EC and its 
adjacent ECs would trigger release of intercellular growth and differentiation factor, so that 
the resident EC gets to be activated and proliferated [8]. However, with the presence of more 
cardiovascular risk factors, there would not be enough resident ECs that can proliferate to 
repair. A replenishment of damaged ECs by injecting exogenous endothelial progenitor cells 
(EPCs) is believed to be promising in future clinical therapy. The role of EPCs in vascular 
repair is stated in the next section. 
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Figure 1-2. 
 
 
Figure 1-2. Differential roles of modest (“good”) and high (“bad”) levels of NO•. The 
“good” NO• produced from eNOS with its co-factor BH4 induce sGC/cGMP in SMCs and 
platelet. Whereas the “bad” NO• generated by eNOS uncoupling or iNOS exacerbate 
oxidative stress and increase peroxynitrite formation to cause various cellular damages. 
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1-3. Endothelial Progenitor Cells in Vascular Repair 
 EPCs were first characterized by Asahara et al. in 1997[9].They can be defined by 
the common surface markers for hematopoietic stem cells (HSCs) and ECs, such as c-Kit, 
Sca-1, CD34, CD133, Tie-2 and VEGF receptor-2 (VEGFR2), confirming that EPCs are 
derived from hemangioblast and capable to differentiate into mature ECs. Bone marrow 
(BM) transplantation studies demonstrated that EPCs derived from BM contribute to both 
physiological and pathological neovascularization. The postnatal neovascularization utilizing 
BM-derived EPCs are seen during tumor growth, wound healing, ischemic muscle healing, 
and cornea micropocket angiogenesis after surgery, as well as in uterus endometrial 
formation[10]. These evidences suggest neovascularization can occur not exclusively by 
proliferating resident ECs but also by incorporating BM-derived EPCs. Those findings from 
BM transplantation also show that EPCs are mainly produced in BM, and mobilize into 
peripheral blood stream and then home to endothelium. Although not yet entirely revealed, 
the recruitment of circulating EPCs is mostly augmented through chemotaxis and adhesion 
mechanisms. The interaction of chemokine receptor CXCR-4,which is expressed on EPCs, 
and its ligand stromal cell-derived factor 1 (SDF-1, also known as chemokine-CXCL-12) is 
the most established pathway in EPC mobilization[11][12]. Other than this chemokine factor, 
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EPCs also express α4-integrins on the membrane and bind to vascular cell adhesion molecule 
1 (VCAM-1), which is expressed on endothelial and stromal cells[13][14]. However, how 
these factors are regulating the downstream signaling to achieve the EPC homing is largely 
unknown. More recent studies reveled the involvement of c-kit phosphorylation in response 
to CXCR-4/SDF-1 and α4-integrins/VCAM-1 binding[15]. Investigation on detailed 
mechanisms of BM-derived EPC kinetics is hampered due to the lack of precise tracking 
method and incomplete characterization and definition. The role of EPCs in postnatal 
vascularization is summarized in Figure 1-3. 
Studies have consistently shown that the number, migratory activity and functions of 
circulating EPCs are compromised in those who have high risk of cardiovascular diseases 
including coronary artery disease and diabetes[16][17][18]. These studies implied the 
importance of EPCs in cardiovascular disease diagnosis and prognosis. Despite the fact that 
the remained questions in EPC molecular biology, several clinical studies of cell therapy had 
been conducted soon after discovery of BM-derived EPCs [19][20], but still have not reached 
to satisfaction in clinical applications (Table 3 in ref [21]). Therefore, improved means of 
transplantation of EPCs are required in patients without causing potential complication. One 
of the major concerns in the effective EPC delivery deals with disturbance from oxidative 
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stress, which is increased in patients with cardiovascular diseases. Functions of EPCs are 
impaired in the presence of ROS [22][23]. Thus, even though the enough number of EPCs is 
injected to patients with cardiovascular diseases, cells would undergo apoptosis and reduce 
the probability of sufficient homing to the desired site to promote re-endothelialization. 
Moreover, such suboptimal microenvironment can cause worse secondary effects from 
inflammatory cytokines generated by EPC apoptosis. It is obvious that simply increasing the 
number of EPC for delivery cannot solve the problem. A great effort has been made to 
optimize the method of EPC administration (Table 4 in ref [21]), but further addressing the 
way to protect EPCs from oxidative stress is desperately required. Indeed, NO
•
 bioavailability 
and scavenging ROS by inactivating NADPH oxidase and by upregulating superoxide 
dismutase (SOD) maybe beneficial [24][25][26]. NO
•
 production from EPC itself is also 
proved to exert antioxidant effect and protect vascular from further endothelial injury [27]. 
Hence, refining the method of administration as well as pre-conditioning of EPCs to protect 
them from oxidative stress would be effective approaches to improve EPC-dependent 
therapeutic applications. 
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Figure 1-3. 
 
Figure 1-3. Neovascularization by EPC mobilization and recruitment. EPCs are derived 
from bone marrow and mobilize into peripheral blood circulation. Chemotaxis and/or 
adhesion molecules such as SDF-1 and VCAM-1 mediate EPC recruitment onto the 
endothelium to promote vasculogenesis. 
The figure is modified from Kawamoto A & Asahara T, Catheter Cardiovasc Interv. (2007) 
and Cheng M & Qin G, Prog Mol Biol Transl Sci. (2012)  
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1-4. Endothelial Protective Effect of Netrin-1 
Netrins were originally identified as a family of endogenous axon guidance molecule 
in 1990 by a genetic study using Caenorhabditis elegans [28]. Later netrins were found in 
other organisms and demonstrated to be secreted by floor plate cells, which promote 
circumferential spinal commissural axons during development [29][30]. Netrins are laminin 
related proteins in which N-terminal domains V and VI are homologous to each other[31]. 
The V domain in N-terminus consists of 3 epidermal growth factor (EGF) domains. Netrins-1, 
-2 and -3 are homologous to γ chain of laminin, whereas netrins-4, -G1 and G2 are 
homologous to β chain of laminin. Netrin-1 is the most extensively studied member of the 
family, and crystal structure studies of netrin-1 revealed that V and VI domains are 
responsible for its receptor binding [32][33]. There are two major receptors of netrin-1, 
Deleted in Colorectal Cancer (DCC) and UNC5B from UNC-5 family proteins. DCC and 
UNC5B are found to show an opposed response in cell migration, attractive and repulsive, to 
the concentration of netrin-1. Other than such biphasic chemotactic mechanism, DCC and 
UNC5B are known to be dependence receptors, meaning that unbound receptors could induce 
apoptosis instead of being quiescent and exhibiting pro-apoptotic effect in the presence of 
ligand netrin-1 [34].These features have made netrin-1 a unique molecule among other axon 
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guiding cues, such as ephrins, semaphorins and slits. Netrin-1 have been also found in 
various tissues outside of the central nervous system such as pancreas, mammary gland, lung, 
muscle, and vasculature [35]. Our studies have been focusing on the effect of netrin-1 in the 
cardiovascular system, specifically endothelial cells. (Netrin-1 and its receptor structures: see 
Figure 1-4) 
 The importance of netrin-1 in vascular cells began to take notice because of the 
findings on common molecular mechanisms between vascular and neural network formations. 
Not only the structure formation of lamellipodia and filopodia at axonal growth cones and 
endothelial tip cells are similar, but later it was found that they share molecular cues for 
growth guidance as well[36].While three other axon guidance cues ephrin, semaphorin and 
slit were demonstrated to have angiogenic activity one after another, the angiogenic role of 
netrin-1was also revealed in 2004[37][38]. Subsequently, our group showed this role of 
netrin-1 was mediated by the dominant expression of DCC in aortic endothelial cells and 
consequent activation of the mitogen activated protein kinase ERK1/2 and NO
•
 production 
via eNOS phosphorylation (Figure 1-5) [39]. As mentioned above, since NO
•
 production in 
endothelial cells is known to have mitogenic effect on endothelial cells, we speculated that 
netrin-1 can be a strong therapeutic candidate in cardiovascular diseases by restoring 
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endothelial dysfunction. Our group and others have published a substantial number of studies 
demonstrating the protective effect of netrin-1 on cardiovascular systems thus far 
[40][41][42][43], which suggests the promising utilization of netrin-1 in clinical therapy. 
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Figure 1-4.  
 
 
Figure 1-4. The structure of netrins and netrin receptors. Netrins are laminin related 
molecule that consist of three domains, V, VI, and C. Note that netrin-1 is homologous to the 
γ-chain of laminin N-terminus. Representative receptors, DCC and UNC5, are single-ass 
transmembrane proteins. Netrin-1 binds to extracellular domain of these receptors. 
Figure is adopted from Ko SY et al, Trends Mol Med. (2012)  
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Figure 1-5. 
 
 
Figure 1-5. Netrin-1 induces angiogenesis via DCC/ERK1/2/eNOS/ NO
•
 signaling 
pathway. Netrin-1 binding to DCC activates ERK1/2, and subsequently eNOS 
phosphorylation at serine 1179 to produce NO
•
. Further, NO
•
 activate ERK1/2 to form a 
feed-forward cycle. This signaling cascade induces endothelial mitogenic responses. 
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2. Vascular protective effect of netrin-1 
As stated in the last section of the previous chapter, the protective effect of netrin-1 
has gained a solid amount of evidence. In the following part of this chapter, the article 
“Attenuation of neointimal formation with netrin-1 and netrin-1 preconditioned endothelial 
progenitor cells”, published in Journal of Molecular Medicine (March 2017, Volume 95, 
Issue 3, pp 335–348), with some of additional supporting information is presented. In this 
issue, we addressed more direct molecular mechanisms of netrin-1 in vascular endothelial 
recovery using femoral artery wire injury model mice to simulate restenosis followed by 
endothelial injury (Figure 2-1). The article also investigated the effect of netrin-1 on EPC  
function for the first time.  
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Figure 2-1. 
 
Figure 2-1. Femoral artery wire injury model. A guide wire was inserted from a small 
incision at the branch between the rectus femoris and vastus medialis muscles. Then the wire 
was left inserted for 1 min, 3 times to denude endothelial cells. The wound is closed by 
suturing. 
This figure is modified from Sata M et al, J Mol Cell Cardiol. (2000)  
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2-1. Introduction  
Restenosis is a serious clinical problem as an untoward result of angioplasty, which 
is commonly performed in patients with myocardial infarction or severely occluded coronary 
artery. It is a major complication after angioplasty treatment of myocardial infarction. In 
order to prevent occurrence of restenosis/ re-occlusion of the coronary artery, different kinds 
of drug eluting stents (DES) have been developed. Although DES reduced the occurrence of 
in-stent restenosis compared with bare-metal stents, it raises the concern that most of drugs 
used in DESs inhibit re-endothelialization to promote thrombosis [1], which can be 
associated with more mortality. Hence, novel therapeutic strategies are in urgent need to  
prevent cardiovascular complications derived from restenosis. 
The reason that restenosis remains unsolved clinically is likely attributed to its 
intricate mechanisms. Restenosis is primarily triggered by the damage of the endothelium 
that induces inflammatory response and thrombosis, followed by vascular smooth muscle cell 
(VSMC) proliferation and migration, and extensive vascular remodeling [2]. The 
endothelium has a crucial role in regulating vascular tone and structure by synthesizing nitric 
oxide (NO
•
) from endothelial NO synthase (eNOS), which is known to be a vasodilator with 
antiinflammatory and anti-thrombotic properties. NO
•
 produced in the endothelium activates 
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cyclic GMP (cGMP) and cGMP-dependent protein kinase in VSMC, which induce 
vasodilatation as well as inhibition of VSMC proliferation and migration. Therefore, 
augmentation of NO
•
 action at physiological levels may have good potential for attenuating 
restenosis. Nonetheless, none of the currently available therapies could ensure modest and 
continuous release of NO
•
. For example, nitroglycerin releases NO
•
 quickly but transiently to 
relieve chest pain associated with angina. Overdosing, however, leads to side effects such as 
severe hypotension [3]. In addition, it has been shown that many patients develop nitrate  
tolerance to become insensitive to the treatment [4]. 
Previously, our group have shown that netrin-1, originally discovered as an 
axon-guiding molecule [5, 6], exerts potent angiogenic and cardioprotective effects via the 
production of NO
•
, mediated by DCC/ERK1/2 dependent activation of eNOS [7–9]. Binding 
of netrin-1 to DCC activates ERK1/2 to produce NO
•
 by phosphorylation of eNOS at serine 
1179 residue [8]. Further, production of NO
•
 in turn activates DCC or ERK1/2 pathway, 
resulting in a feed-forward mechanism to contribute to cardioprotective or angiogenic 
signaling [7–13]. Therefore, it is reasonable to hypothesize that netrin-1 may prevent  
restenosis following endothelial injury, via the protective effect of NO
•
. 
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In the present study, we examined the effects of netrin-1 on neointimal formation 
using a femoral artery wire injury model that simulates angioplasty procedure [14]. Netrin-1 
infusion into femoral artery injured mice markedly attenuated neointimal formation in a 
DCC/NO
•
-dependent manner. VSMCproliferation in situ was reduced.  We further 
demonstrated an inhibitory effect of netrin-1 on VSMC migration, via a NO
•
/cGMP/p38 
MAPK pathway. In addition, netrin-1 infusion accelerated timely EPC homing after injury. 
Injection of netrin-1 preconditioned wild-type EPCs, but not EPCs of DCC
+/−
 animals, 
largely abrogated neointimal formation. Proliferation, NO
•
 production, and resistance against 
oxidative stress-induced apoptosis of EPCs were significantly augmented by netrin-1. Taken 
together, our data for the first time establish that netrin-1 can serve as a potent vascular 
protective agent against restenosis after endothelial damage, and its effects are mediated by 
NO
•
-dependent inhibition of VSMC migration and augmentation of EPC functions.  
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2-2. Methods 
Animals 
All animal procedures were approved by the Institutional Animal Care and Usage Committee 
at the University of California, Los Angeles. Six- to eight-week-old male C57BL/6 mice 
from Charles River Laboratories (Wilmington, MA) were used. Animals were housed in a 
pathogen free facility, with food and water ad labium, and under a 12-h light/dark cycle. 
 
Reagents  
Netrin-1 (#1109-N1) was purchased from R&D Systems (Minneapolis, MN). Antibodies of 
proliferating cell nuclear antigen (PCNA/#sc-56) and Flk-1 (#sc-19530) were purchased from 
Santa Cruz (Dallas, TX). CD34 antibody (#ab8158) and GFP antibody (#ab290) were 
obtained from Abcam (Cambridge, MA), and Alexa Fluor 594 conjugateIsolectin GS-IB4 
antibody (#I21413) was purchased from Life Technologies (Carlsbad, CA). CD133 antibody 
(#orb10288) was obtained from Biorbyt (San Francisco, CA). P38 MAPK inhibitor 
SB202190 (#559388) and JNK inhibitor SP600125 (#420119) were purchased from EMD 
Millipore (Germany). ERK1/2 inhibitor U0126 (#U120), cGMP antagonist Rp-8-Br-PET- 
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cGMPs (#B6684), NO scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 
(PTIO), anti-von Willebrand Factor (vWF) antibody (#F3520), and anti-actin antibody 
(#A2066) were all purchased from Sigma. Antibody for p38 MAPK (#506123) was obtained 
from Calbiochem. Antibodies for phospho-p38 MAPK (#9211), alpha-Tublin (#2125), eNOS 
(#9586), and phospho-eNOS (Ser1179) (#9571) were all purchased from Cell Signaling 
Technology (Danvers, MA). Goat anti-rabbit IgG-HRP conjugate (#172–1019) was obtained 
from Bio-Rad (Irvine, CA). Other chemicals were obtained from Sigma in the highest purity. 
 
Surgical procedures—osmotic pump 
Animals were anesthetized in a closed chamber filled with isoflurane, then quickly moved to 
a breathing mask supplied with 95%:5% O2/CO2 mixed with 1.5% isoflurane. Hair between 
the shoulder blades was removed using a hair removal lotion (Nair, Princeton, NJ), then 
disinfected using an iodine solution. A small incision was made in this area and a 4-week 
release osmotic pump (Durect Corp) was inserted into the left flank. Pumps were filled with 
either vehicle or netrin-1 (15 ng/ day, 1109-N1, R&D Systems, Minneapolis, MN). Femoral 
wire injury was performed a day after the insertion of the osmotic pump to allow for the  
pretreatment of netrin-1. 
  32 
 
Surgical procedures—femoral wire injury model 
Animals were anesthetized as described above. After checking for proper anesthesia, the 
animal was turned on its back and restrained using surgical tape. Hair on the thigh area was 
removed using a hair removal lotion (Nair), then disinfected using an iodine solution. An 
incision was made on the right thigh area above the femoral artery. The femoral artery was 
then isolated and cleared of connective tissue. Blood flow is temporarily stopped using a 
small artery clamp, and an incision was made on a branch between the rectus femoris and 
vastus medialis muscles [14]. A fixed core wire guide coated with heparin was inserted into 
the artery and moved up. The artery clamp was then removed and the wire moved up toward 
the iliac artery. The wire was then allowed to stay for 60 s, then pulled back towards the 
incision point. This insertion and pulling back were repeated for a total of three times. At the 
end of the third time, the artery was once again clamped and the wire guide pulled out of the 
artery. The incision site on the artery was then ligated using surgical silk (5–0 Vicryl). The 
skin was then closed and sutured together, then sealed with surgical glue. A similar procedure 
was performed on the left leg, with the exception that the wire was not inserted into the 
artery. 
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 The femoral artery from the left leg was used as control. 
 
Tissue processing 
After euthanasia via CO2, animals were injected with 0.1 mL of heparin and flushed of blood 
using ice-cold PBS via the left ventricle. The animals were then perfused with 4% 
paraformaldehyde. Both femoral arteries were removed from the body and fixed overnight in 
4% paraformaldehyde, prior to being embedded in paraffin and sectioned at 5 μm. For 
histological analysis on acute samples, harvested femoral arteries were directly embedded in  
OCT and subjected to slicing at 5 μm by cryostat sectioning 
 
H&E staining and immunostaining 
H&E staining was performed by the Translational Pathology Core Laboratory Core Facility 
at UCLA using standard protocols, following sectioning. Further, PCNA immunostaining 
was performed using VECTASTATIN ABC Kit (Vectr Laboratories, Burlingame, CA). To 
observe the acute response after injury, CD34 and Isolectin GS-IB4 antibodies were used to 
detect homing EPCs and mature endothelial cells, respectively, on 1-h post-injury tissues. In 
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addition, EPCs isolated from GFP transgenic mice were also subjected to netrin -1 
preconditioning prior to injection, and the homing to the wound site was determined by  
co-staining with anti-GFP antibody and anti-Isolectin GS-IB4 antibody.  
 
Quantification of neointimal formation 
Using Image J software, the areas of the intimal and medial layers were measured manually. 
Ratio of intima to media was used for quantitative assessment of neointimal formation. 
 
Nitric oxide radical detection by electron spin resonance  
Bioavailable NO
•
 radical in femoral arteries and EPCs was detected using electron spin 
resonance (ESR) as previously described [8, 15] with modifications for the current 
experimental setup. For in vivo experiments, femoral arteries from four animals were 
combined for one experimental data point. NO
•
 production was measured from non-injured 
with or without netrin-1 injection (100 ng/ml of recombinant netrin-1 injected via the tail 
vein immediately after femoral injury surgery) and injured with or without netrin-1 injection. 
For in vitro experiments using EPCs, two 10-cm culture dishes were combined for each 
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group. The tissues or cells were incubated with freshly prepared NO
•
-specific spin trap Fe
2+
 
(DETC)2 (0.5 mmol/L) colloid in modified Krebs/HEPES buffer with 50 μM (femoral artery) 
or 10 μM (EPCs) of calcium ionophore A23187 (Sigma, St Louis, MO) at 37 °C for 3 
(femoral artery) or 1.5 (EPCs) hours. After incubation, tissues or cells were snap frozen in 
liquid nitrogen, then loaded into a finger Dewar for ESR measurement. The instrument 
settings were as follows: bio-field, 3410.00 G; field sweep, 100 G; microwave frequency, 
9.79 GHz; microwave power, 13.26 mW (6 dB); modulation amplitude, 9.82 G; resolution,  
512 points; and receiver gain 356.  
 
Co-culture of VSMCs and endothelial cells  
Rat aortic smooth muscle cells (Lonza, Switzerland) were cultured in DMEM/F12 medium 
(Invitrogen) containing 15 ng/ml of amphotericin and 10% fetal bovine serum to confluence 
and starved in serum-free medium overnight before experiments. Bovine aortic endothelial 
cells (BAECs) (CellSystems, Kirkland, WA) were cultured as described previously [16]. 
Confluent VSMCs and endothelial cells were mixed together with equal cell number for  
migration assay.  
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VSMC migration assay  
Transwell migration chamber (8-μm pore size, Corning) in 24-well plates was used for 
migration assay. Confluent cells were starved with serum-free medium overnight prior to 
plating to the upper chamber. Co-culture of VSMCs and endothelial cells were seeded at a 
density of 2–2.5 × 105 cells/well on the top of the insert in 350 μl of serum-free culture 
medium, while 1 ml of 5% FBS medium containing pharmacological inhibitors [U0126 (50 
μM), SB202190 (10 μM), SP600125 (10 μM), Rp-8-Br-PET-cGMPs (10 μM) and PTIO (60 
μM)] was placed in the lower chamber. After 30 min of incubation, netrin-1 (100 ng/ml) was 
added into the medium in the lower chamber. The plates were then incubated for 24 h, 
followed by treatment of the cells with a dissociation buffer (Trevigen, Gaithersburg, MD) 
containing calcein AM (Calbiochem, Germany) to detect and quantify the fluorescence of 
migrated cells. The fluorescence were measured in a Bio-Tek fluorescence plate reader set at 
an excitation wavelength of ~485 nm and an emission wavelength of ~520 nm with triplicate 
readings.  
 
Wound healing assay on separately co-cultured VSMC with EC 
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Instead of mixing BAECs and VSMCs together, we also cultured 2 types of cells separately 
toinvestigate proliferation/migration activity only from VSMCs. The bottom surface of 24 
mm polyester membrane transwell inserts with 0.4 μm pore (Corning) was coated with 0.05% 
gelatin, and BAECs were seeded on top of the bottom surface by placing the inserts 
up-side-down. After culturing BAECs on the transwell membrane for overnight, the insert 
was placed back to a normal 6 well-plate containing culture medium, and continued to culture 
until confluent.   Whereas VSMCs were cultured on 6 well-plate till more than 80 % 
confluent. When the both cells are ready, a scratch was made on VSMCs using 1 mL pipet tip. 
Culture medium for VSMCs were replaced to low glucose (1 g/L) DMEM since BAECs 
could be damaged by the high dose of glucose. Then the scratch on VSMCs were imaged 
using Nikon Eclipse Ti confocal microscope. After imaging the initial state of wound, 
VSMCs were pre-treated with or without SB202190 (10 μM), Rp-8-Br-PET-cGMPs (10 μM) 
and PTIO (60 μM), while BAECs were treated with or without netrin-1 (100 ng/mL). Thirty 
minutes later, the transwell inserts with BAECs were replaced on the 6 well-plate contains 
VSMCs and incubated at 37 °C with a 5% CO2 incubator for 24 hrs. Another image of the 
wound was taken after 24 hrs and the area of wound healing was calculated using ImageJ.  
The illustrated figure of this experiment is shown in Figure 2-2. 
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Western blot analysis on co-cultured cells 
Co-cultured cells were starved overnight in 0.5% FBS containing DMEM, incubated with or 
without Rp-8-Br-PETcGMPs (10 μM, 30 min), and then exposed to netrin-1 (100 ng/ml) for 
24 h. After treatment, cells were harvested and lysed, and subjected to detection of total p38 
MAPK and phospho-p38 MAPK protein levels by Western blotting per standard protocols 
using 12% SDS/PAGE and nitrocellulose membranes. Antibody dilutions used were as 
follows: p38 MAPK (1:1000) and phospho-p38 MAPK (1:1000); alpha-Tublin (1:1000) was 
used as internal control. Goat anti-rabbit IgG-HRP conjugate (1:3000) was used as the 
secondary antibody. The blotting results were quantified using ImageJ, normalized to alpha- 
Tublin, and statistically analyzed from four independent experiments. 
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Figure 2-2. 
 
Figure 2-2. Scratch assay in separate co-culture system of BAEC and VSMC. BAECs 
were cultured on the bottom surface of transwell by placing it up-side-down. The tranwell 
was replaced on 6 well-plate for continuing culture of BAECs. VSMCs were cultured on the 
bottom of a different 6 well-plate. The transwell with BAECs was transferred on the culture 
plate with VSMCs before scratch assay. A scratch was made on VSMC with 1 mL pipet tip.  
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EPC isolation and culture 
Mononuclear cells were collected from bone marrow of femur and tibia of 6–8-week-old 
C57BL6 mice (WT) or DCC
+/−
 mice using density centrifugation and cultured in EGM-2 
medium (Lonza). The non-adherent cells were removed after 48 h, and then colony forming 
cells became confluent on the culture plate after 7–10 days. EPCs were characterized by 
immunocytochemical staining with CD34, CD133, Flk-1, and vWF antibodies. The receptor 
expression response to netrin-1 was investigated on cultured EPCs.Cells were harvested 30 
min after treating with or without netrin-1 (100 ng/mL) and extracted proteins per standard 
western blot protocol. Anti-DCC antibody (Santa Cruz Biotechnology/ 1:100 dilution) and 
anti-UNC5B antibody (Enzo Life Sciences/ 1:500 dilution) were used to detect their  
expression in EPCs. 
 
EPC injection 
Primarily, cultured EPCs isolated from WT or GFP transgenic mice were preconditioned with 
netrin-1 (100 ng/ml, 1 h) and 500 of the unconditioned and conditioned cells were injected 
through the tail vein of the animal immediately after femoral injury surgery. One hour or 4 
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weeks later, femoral arteries were harvested and processed for histological analyses of 
immunofluorescent or H&E staining, and re-endothelialization or the intimal growth was  
quantified.  
 
EPC proliferation assay  
EPCs from DCC
+/+
 and DCC
+/−
 animals were seeded at an initial density of 1.0 × 10
5
 
cells/well in 12-well plates and incubated at 37 °C with a 5% CO2 incubator. After overnight 
incubation to allow cells to attach to the bottom of the plates, cells were starved with 5% FBS 
contained endothelial growth basal medium-2 (EBM-2) for 12 h. Then, cells were 
additionally incubated with or without netrin-1 (100 ng/ml in 5% FBS contained EBM-2 
medium) for 24 h, following a pretreatment with or without PTIO (60 μM, 30 min). At the 
end of the incubation, cells in each well were resuspended following trypsinization and 
counted using a hemocytometer. Individual experiment was prepared in triplicate and was  
repeated three times.  
 
EPC apoptosis assay—caspase 3 assay 
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EPCs from DCC
+/+
 and DCC
+/−
 animals were seeded at approximately 1.0 × 10
5 
cells/well in 
24-well plates and cultured for 3 to 4 days till the cells become more than 90% confluent. 
Cells were then starved with 5% FBS contained EBM-2 medium. After overnight starvation, 
medium was discarded and replaced with PBS with or without PTIO (60 μM, 30 min) and/or 
netrin-1 (100 ng/ml, 30 min), and then exposed to hydrogen peroxide (H2O2, 500 μM) for 30 
min. Caspase 3 activity was assessed with a fluorimetric caspase 3 Assay Kit (Sigma), 
following the manufacturer’s instruction. Briefly, cells were suspended into tubes with lysis 
buffer. Assay buffer and caspase 3 substrate Ac-DEVD-AMC were added and the sample 
mixtures were transferred to a black 96-well plate along with substrate blank and caspase 3 
positive control. The fluorescent signal from AMC, which is the hydrolysed substrate by 
caspase 3, was detected at excitation of 360 nm and emission of 460 nm every 10 min for 1 h.  
 
EPC apoptosis assay—TUNEL assay  
APO-BrdU TUNEL assay (Invitrogen) was performed using the identically treated EPCs 
subjected to caspase 3 assay. The kit detects the DNA fragmentation of apoptotic cells by 
reacting terminal deoxynucleotidyl transferase (TdT) and thedeoxythymidine analog 
(BrdUTP) to label the break sites. The incorporated BrdU at DNA break sites was detected 
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by an Alexa Fluor 488 dye-labeled anti-BrdU antibody. Therefore, the Alexa Fluor 488 dye 
along with propidium iodide (detects the total cellular DNA content) was imaged with the  
Nikon Eclipse Ti confocal microscope.  
 
eNOS phosphorylation in EPCs  
Alongside, NO radical detection by ESR, eNOS phosphrylation at serine 1179 in mouse 
EPCs was examined using Western blot analysis. Antibody dilutions used were as follows: 
eNOS (1:500) and phospho-eNOS (Ser 1179) (1:500). Actin (1:10,000) was used as an 
internal control. Goat anti-rabbit IgG-HRP conjugate (1:3000) was used as the secondary  
antibody.  
 
Statistics  
All statistics were performed using Prism software. Comparisons between two groups were 
performed using t tests, with a significance level of 0.05. Comparisons among multiple 
groups were performed using ANOVA, with Newman-Keuls as the post hoc test and a  
significance level of 0.05.  
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2-3. Results  
Netrin-1 infusion markedly attenuated neointimal formation post endothelial injury 
To test whether netrin-1 induces protection against neointimal growth, femoral wire 
injury was performed on animals that were infused with netrin-1 or vehicle. Intima to media 
ratio (averaged at 0.15 ± 0.05 for intact vessels) was 1.98 ± 0.47 at 4 weeks after surgery in 
vehicle-treated animals, while netrin-1 infusion markedly decreased this ratio to 0.64 ± 0.14 
(Figure. 2-3A, B). Netrin-1 was also effective in reducing neointimal growth even at week 1. 
The representative H&E images of the vessels which are shown in Figure. 2-3A, C, D 
demonstrate that VSMC proliferation in situ, labeled by PCNA, was significantly increased 
in wire injured femoral arteries. This was, however, largely prevented by netrin-1 infusion. 
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Figure 2-3.  
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Figrue 2-3. Netrin-1 infusion significantly inhibits neointimal growth after femoral 
artery wire injury. Femoral Femoral artery was injured by the passing of a guide wire, and 
netrin-1 was infused via an osmotic minipump.  Femoral arteries were harvested after 1 or 4 
weeks, fixed in paraformaldehyde, and sectioned and stained for H&E and PCNA antibody.  
A) Representative H&E images. B) Grouped data of intima to media ratio.  Data show that 
at 1 and 4 weeks, netrin-1 infused animals had significantly smaller intima to media ratio in 
the wire damaged artery, indicating inhibition of neointimal growth. n=4 -8. 
*p<0.05 ,**p<0.01 C) Representative images of immunohistochemical staining. PCNA 
positive cells are stained with dark brown in color. D) Grouped quantitative data of 
PCNA-positive cells to whole tissue ratio. Netrin-1 infused animals had significantly less 
PCNA both at 1 and 4 weeks post-injury. n=4-7. **p<0.01, ***p<0.001 v.s. CTRL in 1  
week, 
#
p<0.05, 
$$
p<0.01  
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Netrin-1’s protective effect against neointimal formation is dependent on DCC 
To test whether netrin-1 receptor DCC is involved in the protective effect to 
attenuate neointimal formation, similar experiments described above were performed in 
DCC
+/+
 and DCC
+/−
 animals. The results, shown in Figure. 2-4A for representative H&E 
images and Figure. 2-4B for quantitative data, indicate that netrin-1’s inhibition on 
neointimal growth was abolished in DCC
+/−
 animals. This confirms that DCC is the receptor 
through which netrin-1 exerts its vascular protective effects against wire-induced endothelial  
injury.  
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Figure 2-4. 
 
Figure 2-4. Netrin-1’s protective effect against neointimal growth is mediated by the 
receptor DCC. Netrin-1 was infused via an osmotic minipump into DCC
+/+
 and DCC
+/-
 mice 
that received a femoral wire injury.  The femoral arteries were harvested 4 weeks later, fixed 
in paraformaldehyde, sectioned, and stained for H&E.  A) Representative H&E images;B) 
Grouped data for intima to media ratio from DCC
+/+
 and DCC
+/-
 animals, indicating that 
netrin-1 induced attenuation of neointimal growth was absent in DCC
+/-
 mice.  n=4-9 each,  
*p<0.05, **p<0.01  
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 Netrin-1 significantly induces NO
•
 production in femoral arteries  
In previous studies in our laboratory, we found that netrin-1 can increase NO 
production both in cells [8] and tissue [7, 9–13]. Since NO• is known to attenuate neointimal 
formation [16, 17], we hypothesized that NO
•
mediates netrin-1’s inhibitory effect on 
neointimal formation in the wire injury model. Here, we measured NO
•
production using ESR 
from femoral arteries 1 h after injury, in the presence or absence of netrin-1 intravenous 
injection (immediately after surgery, 100 ng/ mL blood). As shown in Figure. 2-5, we 
observed a 38.5% reduction in NO
•
bioavailability in the injured femoral arteries, indicating 
loss of endothelium and eNOS. Netrin-1 treatment elevated NO
•
production in both injured 
and non-injured vessels, implicating potent activation of eNOS in both intact and partially  
remained endothelium.  
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Figure 2-5. 
 
 
Figure 2-5. Netrin-1 infusion increases NO production. Netrin-1 was injected via tail vein 
immediately after injury. The harvested 1 hr post-injured femoral arteries were incubated in 
the spin trap solution for 3 hours before electron spin resonance (ESR) determination of NO 
production. A) Representative ESR spectra; B) Grouped data for NO production.  n=4-10  
each, *p<0.05, ***p<0.001, vs. CTRL, intact, 
###
p<0.001, vs. CTRL, injured 
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Netrin-1 inhibits VSMC migration via an NO
•
-dependent mechanism 
Migration of VSMC is one of the major events that leads to abnormal intimal 
growth after endothelial damage. In a previous study, we demonstrated increased 
NO
•
production in netrin-1 endothelial cell [8], which has been shown to be a potent inhibitor 
of VSMC migration. Hence, we examined whether netrin-1’s protective effect on neointimal 
growth is related to inhibition of VSMC migration by NO
•
. We co-cultured VSMCs with 
endothelial cells, treated the cells with vehicle, netrin-1, or netrin-1 in combination with 
PTIO, an NO
•
scavenger, and then the migrated cells were dissociated and quantified by 
detecting fluorescence from calcein AM. The results, shown in Figure. 2-6A, demonstrate 
that netrin-1 significantly and reproducibly inhibited cell migration from these co-cultures. 
Further, co-treatment with PTIO largely abolished this inhibition, suggesting that netrin-1’s 
effect on VSMC migration is mediated via NO
•
. We further examined the downstream 
signaling pathways that lead to the inhibition of migration in VSMCs by pretreating VSMCs 
with inhibitors against cGMP, and those of major mitogenic pathways. The results in Figure. 
2-6A show that while inhibitors against ERK1/2 and JNK had no effect on netrin-1’s 
inhibition of VSMCmigration, blockade of cGMP and p38 MAPK signaling abolished  
netrin-1’s effect.  
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Although the mixed co-culture presented above is simulating the actual biology of 
vascular where the endothelial cells and VSMCs are attached to each other, it is also 
important to focus on the kinetics of VSMCs influenced by the secondary effect generated 
from endothelial cells. In this context, our purpose was to deliver NO
•
 produced from 
endothelial cells by netrin-1 treatment and diffuse into VSMCs. Therefore, transwell insert 
was used in this experiment (experimental model: Figure 2-2). VSMCs were modestly but 
significantly inhibited the wound healing by co-culturing with netrin-1 treated BAECs, but 
this effect was diminished by pre-treating VSMCs with PTIO, cGMP antagonist, and p38 
MAPK inhibitor (Figure 2-6C, D). This result is reproducing the mixed co-culture 
experiments, confirming the involvement of p38 MAPK and cGMP in inhibition of VSMC  
migration by NO
•
 production in endothelial cells treated with netrin-1. 
We next examined the relationship between cGMP and p38 MAPK. Using Western 
blotting, we examined the phosphorylation levels of p38 MAPK in the EC-VSMC co-cultures 
treated with netrin1 in the absence or presence of the cGMP antagonist. The results in Figure. 
2-6b demonstrate that cGMP antagonist attenuated p38 MAPK activation, implicating a NO
•
/ 
cGMP/p38 MAPK pathway in mediating netrin-1- induced inhibition of VSMC migration. 
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Figure 2-6. 
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Figure 2-6. Netrin-1 inhibits migration of vascular smooth muscle cells.   
Vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) were co-cultured in equal 
cell numbers. Cell migration was measured using transwell assay.  A) VSMC migration 
from VSMC/EC co-cultures treated with netrin-1 in the absence or presence of 
pharmacological inhibitors (PTIO (60uM) as NO scavengers, and inhibitors for p38 MAPK 
(10uM), cGMP (10uM), ERK (50uM), JNK (10uM)) **p<0.05, n=3-4.  Data indicate NO, 
cGMP and p38 MAPK-dependent attenuation of VSMC migration by netrin-1.  B) Western 
blot analysis for p-p38 MAPK/p38 MAPK in netrin-1 treated co-cultures in the presence or 
absence of cGMP antagonist Rp-8-Br-PET-cGMPs, indicating cGMP lies upstream of p38 
MAPK.  n=3, *p<0.01, **p<0.05 vs. netrin-1 C) VSMC wound healing assay was 
performed with a separate co-culture system showed in Figure 2-2. D) The quantitative result  
of C) from n=6. ** p<0.01, *** p<0.001, vs. netrin-1 treatment alone. 
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Netrin-1 infusion accelerates timely homing of EPCs to the wound site 
Timely re-endothelialization after endothelium damage is critical in the prevention of 
vascular remodeling. Hence, there must be a more acute modification by netrin-1 that helps 
re-endothelialization, so that the inhibition of VSMC migration can be triggered. Figure 2-7 
shows increased expression and colocalization of CD34 (a EPC marker) with Isolectin (an 
EC marker) in netrin-1 infused injured femoral arteries 1-h post-injury and EPC injection 
(Figure. 2-7D’), whereas neither of those were present at the endothelial layer of the injured 
femoral arteries without netrin-1 infusion (Figure. 2-7C’). Therefore, the results indicate that 
netrin-1 accelerated timely homing and re-endothelialization of EPCs to the wound site. To 
further examine homing of EPCs from the injected population, EPCs isolated from GFP 
transgenic mice (GFP-EPCs) were traced after injecting into WT animals by imaging GFP. 
As shown in Figure. 2-7E–G, homing of GFP-EPCs to the injured femoral arteries was 
accelerated by netrin-1 preconditioning. 
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Figure 2-7. 
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Figure 2-7. Netrin-1 accelerated EPC homing after endothelial injury.  Femoral arteries 
were harvested at 1 hr post-injury, with or without netrin-1 pre-infusion. EPC homing was 
evaluated by co-staining with anti-CD34 and Isolectin antibodies.  Shown here are the 
representative immunohistochemical images from each group. A) Intact tissue without 
netrin-1 infusion. B) Intact tissue with netrin-1 infusion. C) Injured tissue without netrin-1 
infusion. D) Injured tissue with netrin-1 infusion. Data indicate accelerated EPC homing, 
implicated by co-localization of CD34 and Isolectin at the endothelial layer of netrin-1 
infused injured femorals, but not on the injured femorals without netrin-1 infusion. Moreover, 
Femoral arteries were harvested at 1 hr post-injury, with or without netrin-1 pre-condition on 
EPC isolated from GFP transgenic mice. EPC homing was evaluated by co-staining with 
anti-GFP and Isolectin antibodies. E) Showing an intact femoral artery from GFP transgenic 
animal as a comparison. F) Injured tissue received GFP-EPC without netrin-1 pre-condition. 
G) Injured tissue received GFP-EPC with netrin-1 pre-condition. Data indicate accelerated 
EPC homing by netrin-1 pre-condition, implicated by co-localization of GFP and Isolectin at 
the endothelium of injured femorals, but not on injured femorals without netrin-1 
pre-conditioning. A’) – D’), F’) and G’) Zoomed-in pictures of selected areas. The pictures 
were inverted due to the use of inverted confocal microscope with 40x object lens.   
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Netrin-1 preconditioned EPCs attenuate wire injury-induced neointimal formation  
EPCs play an important role in the re-endothelialization process [19]. EPCs derived 
from bone marrow mobilize to peripheral circulation and differentiate into mature ECs once 
they attach to the wound site. Therefore, timely recruitment of EPCs to the damaged vessel is 
essential to the prevention of neointimal growth [18]. Hence, another mechanism by which 
netrin-1 may exert its protective effect is via functionalaugmentations of EPCs. Here, we 
examined whether netrin-1 preconditioned EPCs can confer vascular protection. EPCs 
isolated from either DCC
+/+
 or DCC
+/−
 animals were injected into WT mice via tail vein 
immediately after wire injury. The femoral arteries were harvested after 4 weeks to assess 
intima to media ratio. Figure 2-8A shows the characterization of bone marrow-derived EPCs, 
which express CD34, CD133, Flk-1, and vWF. As supporting information to examine 
whether EPCs respond to netrin-1, expressions of two representative receptors of netrin-1, 
DCC and UNC5B, was detected. Figure. 2-8Sshows EPCs does respond to netrin-1 and only 
DCC expression level was significantly increased by netrin-1 treatment, while UNC5B  
protein abundance ramined unchanged. 
Figure 2-8B shows representative H&E images of the femoral arteries, while 
Figure. 2-8C shows summarized data. The results indicate that netrin-1 preconditioned EPCs 
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largely attenuated neointimal formation, which was absent when EPCs isolated from the 
DCC
+/−
 animals were used, suggesting that netrin-1 can directly impinge on EPCs to exert the 
beneficial effect, and that the EPCs also require DCC receptor to respond to netrin-1 
preconditioning. These results implicate a role of EPCs in the repair mechanism and suggest  
that netrin-1 preconditioned EPCs may serve as a potential therapeutic application.  
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Figure 2-8. 
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Figure 2-8. Netrin-1 preconditioned EPCs significantly reduces neointimal growth in a 
DCC-dependent fashion. A) Characterization of EPCs isolated and differentiated from 
mouse bone marrow (Scale: 20 μm).  These EPCs express CD34, CD133, vWF, and Flk-1, 
which colocalize well with each other. Particularly, vWF is localized to Weibel-Palade 
bodies. S1-3) DCC and UNC5B receptor response to netrin-1 was confirmed in cultured 
EPCs using western blot.Netrin-1 treatment at the concentration of 100 ng/mL significantly 
increased the expression of DCC, but no change in UNC5B. B) EPCs isolated from DCC
+/+
 
or DCC
+/-
 mice were preconditioned with netrin-1 (100 ng/ml, 1 hr) prior to being tail vein 
injected into wild type animals immediately after femoral wire injury. The femoral arteries 
were harvested after 4 weeks, fixed, sectioned, and stained for H&E. Showing the 
representative H&E images; C) Grouped data of intima to media ratio, indicating that 
netrin-1 treated EPC markedly attenuated neointimal growth, while this protective effect was  
abolished with EPCs harvested from DCC
+/-
 animals.  
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Netrin-1 significantly improves EPC proliferation  
As endothelial cells are potent inhibitors of VSMC migration, timely regeneration of the 
endothelial layer is critical in preventing neointimal growth after vascular injury. Hence, the 
proliferation of EPCs is one of the critical factors that are involved in re-endothelialization 
and vascular repair. Here, we examined whether netrin-1 can improve proliferation of EPCs. 
The results, shown in Figure2-9A, B, indicate that netrin-1 (100 ng/ml, 24 h) significantly 
increased DCC
+/+
-EPC proliferation by 42%, which was also mediated by NO
•
 as 
NO
•
scavenger PTIO attenuated this response. We have previously shown that netrin-1 can 
promote endothelial cell proliferation and migration through its receptor DCC via an 
ERK1/2- NO
•
pathway [8]. In this study, we examined proliferation of WT EPCs and those 
isolated from DCC
+/−
 animals. The EPCs isolated from DCC
+/−
 mice did not show 
improvement in proliferation in response to netrin-1 treatment (Fig. 2-9B). Therefore, the  
beneficial response to netrin-1 in EPC proliferation requires the presence of DCC.  
 
Netrin-1 significantly improves EPC resistance to oxidative stress-induced apoptosis  
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It has been shown that EPCs are sensitive to oxidative stress-induced apoptosis [19], and its 
number is oftenreduced in patients with coronary artery disease [20, 21]. Therefore, it is 
important to augment the resistance to oxidative stress of EPCs to ensure their viability to 
promote vascular repair. Hydrogen peroxide (H2O2)-induced apoptosis in EPCs was 
measured using a caspase 3 assay. It turned out H2O2 increased caspase 3 activity by 43%, 
which was abolished by netrin-1 treatment (Fig. 2-9C). TUNEL assay also showed a 
significant decrease of H2O2-induced apoptosis in netrin-1-treated EPCs (Fig. 2-9D, 
representative images in Fig. 2-9E). For both assays, the protective effect of netrin-1 was 
absent with PTIO scavenging of NO
•
. These data clearly demonstrate that netrin-1 protects  
EPCs against apoptosis via NO
•
.  
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Figure 2-9. 
 
Figure 2-9. Netrin-1 augments EPC function: increased proliferative activity and 
resistance to oxidative stress induced apoptosis. Netrin-1 was used to pretreat the cells for 
30 min prior to H2O2 stimulation. Cells were cultured with PTIO (60 µM) for 30 min before 
netrin-1 treatment in order to scavenge NO generated by netrin-1 treatment. A)  
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Proliferation of wild type EPCs was measured by cell number using hemocytometer.  
Netrin-1 increased the proliferative activity of EPCs, while having no effect on EPCs 
pre-treated with NO scavenger PTIO. n=3, *p<0.001 vs. Netrin-1 in Control group.  B) 
Netrin-1 increases the proliferative activity of EPCs, while having no effect on EPCs isolated 
from DCC
+/-
 animals. n=5-6, *p<0.01, **p<0.001 vs. control of DCC
+/+
 EPCs. C) EPC 
apoptosis measured by caspase 3 activity after the treatment of hydrogen peroxide (500 
µmol/L, 30 min), showing that netrin-1 preconditioning (100 ng/ml) for 30 min significantly 
reduced apoptosis while this response was absent in PTIO pretreated cells. n=3, p<0.05 D) 
EPC apoptosis was measured by TUNEL assay after the treatment of hydrogen peroxide (500 
µmol/L, 30 min), showing that preconditioning of netrin-1 (100 ng/ml) for 30 min 
significantly reduced apoptosis. n=4-6, 
##
p<0.01, 
###
p<0.001 vs. Control, ***p<0.001 vs. 
Netrin-1, 
$
p<0.05, 
$$$
p<0.001 v.s. Netrin-1+H2O2 E) Representative pictures of TUNEL 
assay. Apoptotic cells detected by TUNEL staining is shown in green, whereas total cellular 
DNA detected by PI staining is shown in red. Grouped quantitative data are shown in panel  
D).  
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Netrin-1 induces NO
•
 production and eNOS activation in EPCs  
Enhanced endothelial repair is attributed to the enhanced EPC proliferation, viability, and 
NO
•
production. This EPC-derived NO
•
production has been shown to exert antioxidant action 
and prevent further endothelial injury [22]. Thus, we examined whether NO
•
production 
changes in netrin-1-treated EPCs. Figure 2-10A shows significant upregulation of 
NO
•
production from netrin-1-treated EPCs compared to non-treated EPCs. Further, we 
demonstrated that there is an increase in eNOSs1179 phosphorylation in EPCs treated with 
netrin-1 (Fig. 2-10B). Therefore, netrin-1 promotes EPC function, not only by increasing its 
number and viability but also by improving eNOS activation and NO
• 
production. 
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Figure 2-10. 
 
Figure 2-10. Netrin-1 induces NO production and eNOS activation in EPCs. A) NO 
production from EPCs was measured using ESR. Netrin-1 treatment increased NO 
production by 70%. n=6, p<0.05. B) p-eNOS to eNOS ratio (normalized with beta-actin 
individually) in netrin-1 treated EPCs. Netrin-1 treatment significantly increased the  
phosphorylation of eNOS at serine 1179. n=3, p<0.05 
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2-4. Discussion  
In this work, we examined the vascular protective effects of netrin-1 against 
neointimal growth induced by wire injury in the femoral artery. Netrin-1 infusion abolished 
neointimal formation as assessed by ratio of intimal to medial thickness, when compared to 
untreated controls. This effect was absent in animals lacking the netrin-1 receptor DCC. 
VSMC proliferation in situ was largely attenuated by netrin-1. VSMC migration, one of the 
major events in neointimal growth, was inhibited with netrin-1 and mediated by the 
NO
•
/ cGMP/p38 MAPK pathway.  Rapid  accelerat i on of  EPC homing and 
re-endothelialization were induced by netrin-1. In separate experiments, we injected 
netrin-1-treated EPCs to femoral injured animals, which also reduced the ratio of intimal to 
medial thickness when compared to animals injected with untreated EPCs. We further 
observed that EPCs treated with netrin-1 had improved proliferative activity, increased 
resistance to oxidative stress-induced apoptosis, increased eNOS serine 1179 phosphorylation, 
and elevated NO
• 
production. Overall, these data clearly define a novel and robust effect of 
netrin-1 serving as a vascular protective agent against neointimal formation/restenosis 
following endothelial damage. A schematic summary of the mechanisms that are elucidated  
in this study is shown in Figure. 2-11.  
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Netrin-1 has been shown in the past to have angiogenic properties [8, 23, 24]. In our 
laboratory, we have previously shown that netrin-1 enhances endothelial proliferation and 
migration through a NO
•
-dependent pathway [8]. In this study, we examined whether 
netrin-1’s enhancement of endothelial activity and EPC function can offer protection against 
neointimal formation in a model that simulates angioplasty. Intriguingly, infusion of netrin-1 
resulted in near complete attenuation of neointimal formation, which was absent in animals 
deficient in DCC. This is even more potent than the overexpression of eNOS, which 
attenuated neointimal formation by 70% [25]. Protein S-nitrosothiols that release NO
• 
chronically and locally also attenuates neointimal formation after arterial balloon injury in a 
rabbit model [26]. Combined with our previous notion that relatively modest concentration of 
netrin-1 is optimally cardioprotective, persistent and modest release of NO
• 
from netrin-1 is  
particularly vascular protective.  
Restenosis is a consequence of a series of events triggered by endothelial damage [2]. 
Damage to the endothelium result in a loss of NO
• 
production from eNOS, which plays a 
central role in endothelium-dependent vascular protection [27]. Although VSMCs are 
quiescent under normal conditions, they re-express mitogenic factors under pathological 
conditions such as restenosis and atherosclerosis [28]. Restricted levels of NO
• 
promote 
  70 
VSMC proliferation and migration [29], while inducing vasoconstriction [30]. Migrating 
VSMCs infiltrate to the intimal area and form the intimal cushion. VSMC migration is 
provoked by various factors, such as chemotactic cytokines, growth factors, and extracellular 
matrix components [31]. Our co-culture results demonstrated that cGMP and p38 MAPK are 
sequentially involved in netrin-1 inhibition of VSMC migration. Previous findings indicate 
that p38 MAPK mediates VSMC migration in response to platelet-derived growth factor 
(PDGF) [32] and vascular endothelial growth factor (VEGF) [33]. P38 MAPK has also been 
shown to decrease mitogenic responses in cardiomyocytes [34]. These disparate responses 
reflect varied roles of p38 MAPK in different cell types and in response to different stimuli. 
We further showed that p38 MAPK is downstream of cGMP. The mechanistic details of 
cGMP signaling to p38 MAPK remain to be elucidated, though it has been suggested to occur 
in cardiomyocytes [35, 36]. The other two major MAPK pathways, ERK1/2 and JNK, are 
often studied as pro-proliferative pathways, whereas the p38 MAPK pathway is often 
associated with anti-proliferative pathways [37]. This might explain the distinct response of 
p38 MAPK to netrin-1 among those three MAPKs, suggesting that netrin-1 may play a role 
in inhibiting chemotaxis, rather than DNA synthesis of VSMCs. In addition, loss of NO
• 
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inhibition of inflammatory responses in general would contribute to neointimal formation, 
which can be corrected by infusion of netrin-1 to stimulate NO
• 
production from the  
post-injury remaining endothelial cells. 
The treatment with progenitor or stem-like cells has been shown in the past to reduce 
neointimal growth after vascular injury [18, 38–40]. In one study that also used the femoral 
artery injury model, intravenous injection with iPS-cell-derived Flk-1
+
 cells [39] resulted in 
reduction of neointimal formation when more than 1 × 10
6
 of the cells were injected. In our 
study, we injected only 500 EPCs, which had no significant effect on neointimal formation. 
However, preconditioning of these EPCs with netrin-1 markedly attenuated neointimal 
formation, which could be attributed to augmentations in proliferative activity, resistance to 
apoptosis, and NO
• 
production. After the loss of the endothelium due to vascular injury, the 
timely recovery of the endothelial layer is essential for the restoration of endothelial 
homeostasis, attributed to the potent inhibitory effects on neointimal formation of 
endothelium derived NO
•
[25]. Indeed, we observed the rapid acceleration of EPC homing 
and re-endothelialization in femoral arteries 1 h after endothelial injury and netrin-1 tail vein 
injection. Furthermore, the number of functional EPCs is important for the proper healing of 
the endothelium after vascular repair, while reduced EPC number has been observed in 
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patients with hypertension and coronary artery disease [41]. Oxidative stress develops after 
vascular injury [42]. Therefore, the effect of netrin-1 in improving the resistance to oxidative 
stress-induced apoptosis of EPCs would facilitate survival of the EPCs to enhance repair. 
Taken together, our data also support the use of limited numbers of circulating EPCs for anti- 
restenosis therapy.  
In conclusion, these data establish netrin-1 as a potent vascular protective agent 
against neointimal growth following femoral wire injury of the endothelium. This effect of 
netrin1 is dependent on the receptor DCC for either netrin-1 infusion or treatment with 
netrin-1 preconditioned EPCs. The protection is mediated by NO
•
/cGMP/p38 
MAPK-dependent inhibition of VSMC migration, and augmented functions of EPCs in terms 
of enhanced proliferative activity, increased resistance to oxidative stress-induced apoptosis, 
and increased eNOS phosphorylation and NO
• 
production. These findings may promote usage 
of netrin-1 and netrin-1 preconditioned EPCs as novel therapeutics treating post-angioplasty 
restenosis, which would be highly significant in the management of myocardial infarction at 
 bedside.  
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Figure 2-11. 
 
Figure 2-11. Schematic summary of mechanistic insights of netrin-1 inhibition of 
restenosis. Endothelium injury causes restenosis by reducing NO production from the loss of 
the endothelial cells and subsequently removing its inhibition on VSMC migration. Netrin-1 
treatment inhibits VSMC migration via NO/cGMP/p38MAPK. In situ VSMC proliferation 
was also inhibited by netrin-1 perfusion.  In addition, netrin-1 augments functions of EPCs, 
including proliferation and resistance to oxidative stress, facilitating timely homing of EPCs 
to the wound site. These downstream pathways contribute to marked inhibition of netrin-1 on 
neointimal formation post endothelial injury. 
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3. Protective effect of netrin-1 in atherosclerosis 
 
The protective effects of netrin-1 in the settings of pathophysiological processes of 
angiogenesis and neointimal formation are discussed in the previous chapters. As a next step, 
we tested whether netrin-1 is also effective in the prevention of atherosclerosis. Here we used 
apolipoprotein E null (apoE
-/-
) mice with high fat food feeding. ApoE is a member of plasma 
lipoproteins which transport lipids to various cells and tissues. It is important in cholesterol 
metabolism. ApoE
-/-
 mice spontaneously develop atherosclerotic lesions with a normal chow 
diet, and the lesion develop even more robustly with a western-type diet, leading to a rupture 
of plaques[1]. Although the pathogenesis remains incompletely understood, its certainty of 
atherogenic activity by affecting lipid metabolism and distribution made it one of the 
strongest models to study atherosclerosis. Indeed, apoE
-/-
 mice are used in a great amount of  
research in testing new drug target against atherosclerosis. 
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3-1. Introduction 
Atherosclerosis is a chronic arterial disease, which is one of the most prevalent 
cardiovascular disorders especially in developed countries. The pathogenesis of 
atherosclerosis starts with endothelial damage due to hyperlipidemia. The EC damage 
reduces NO
•
 bioavailability often consequent to increased ROS production. The so called 
“malignant” lipoprotein, low density lipoprotein (LDL) is oxidized (ox-LDL) in such 
environment. ECs are activated by ox-LDL intake, which promotes immune cell attraction 
and leading to increased intake of macrophages that differentiated from monocytes. The 
macrophage and ox-LDL further react together and accumulate as foam cells in 
subendothelial region, which is recognized as fatty streak [2]. Fatty streaks in arterial walls 
contribute gradual development of atheroma and plaques [3]. The plaque can be ruptured and 
form a thrombosis, which would directly lead to a sudden death from heart attack or stroke. 
Not to mention its huge impact on mortality, the tremendous economic burden has urged 
scientists to develop more effective therapeutics. According to National Heart, Lung, and 
Blood Institute, options on atherosclerosis treatment are thus far limited to medications to 
lower the cholesterol levels, and blood pressure and blood glucose levels, and prevention of 
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inflammation and blood clots. In addition, people with high risk factors are recommended to 
have a healthier lifestyle, but medical procedures and surgery such as coronary angioplasty,  
bypass grafting and endarterectomy, are required in some severe cases. 
As indicated above, LDLs, the main blood cholesterol carrier, are oxidized in 
athero-prone environment due to accumulated ROS. Ox-LDLs are the causal substances in 
atherosclerosis progression [4]. They damage various cells including endothelial cells 
therefore inducing endothelial dysfunction. Reduced bioavailability of NO
•
 impairs 
vasodilation, often consequent to pro-inflammatory and pro-thrombotic states. A well-known 
study from Heitzer T et al. demonstrated endothelial dysfunction and defective vasodilatation 
in chronic smokers, who have elevated oxLDLs [5].Moreover, oxLDLs induce apoptosis as 
well as autophagy of endothelial cells both resulting in endoplasmic reticulum (ER) stress 
[6]. Hence, endothelial cells play a key protective role against atherogenesis. 
 As discussed in the previous chapters, netrin-1 protects endothelial cells by 
activating DCC/ERK1/2/eNOS pathway [7]. The function of endothelial progenitor cells 
(EPC) are also promoted by netrin-1 [8]. We found these effects presented by netrin-1 
mediate accelerated repair of endothelial injury [8]. In this chapter, we subsequently  
investigated whether netrin-1 can be a therapeutic option for atherosclerosis. 
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It is important to note that endothelial dysfunction and inflammatory responses are 
major driving forces in the pathogenesis of atherosclerosis[9]. The inflammatory responses 
are activated as a consequence of endothelial dysfunction. Platelet aggregation, which would 
further generate inflammatory cytokines, is attenuated by physiological levels of NO
• 
from 
eNOS activation. Thus, inflammatory activation is induced due to endothelial dysfunction in 
atherosclerosis. When platelets are activated by attaching to the arterial wall, it also attracts 
monocytes to form platelet-monocyte aggregation. Monocytes represent a major portion of 
immune response, contributing to plaque progression during atherogenesis[10]. Interestingly, 
monocytes express UNC5B, the receptor of netrin-1, implying the expression of netrin-1 by 
endothelial cells may inhibit inflammation by repulsing monocyte recruitment [11]. 
Hence, we hypothesized that netrin-1 treatment in atherogenic animals alleviate or 
delay the progress of atherosclerosis, via endothelial protection and inhibition of monocyte 
adhesion. Atherogenic mice are created by feeding apoE
-/-
 mice with high fat for 16 weeks. 
Netrin-1 was infused into the animals for the entire time of high fat diet feeding. The 
pathological responses were evaluated by measurements of the increase in body weight, 
plasma lipid profiles, and histological analyses of aortas. Additional investigation on 
monocyte modification by netrin-1 was also conducted.  
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3-2. Methods 
Reagents 
Mouse recombinant netrin-1 was purchased from R&D Systems (Minneapolis, MN). Assay 
kit for cholesterol, triglyceride and HDL-cholesterol were all purchased from Pointe 
Scientific (Canton, MI). Standard solutions for triglyceride and HDL-cholesterol were also 
purchased from Pointe Scientific. Standards for cholesterol assays were prepared using the 
powder obtained from Sigma-Aldrich (St Louis, MO). The antibody used for macrophage 
staining, Rat Anti-Mouse CD107b (Mac3) was purchased from BD Biosciences (San Jose, 
CA). M1 macrophage marker IL-1β Mouse monoclonal antibody and M2 macrophage 
marker Arginase-1 Rabbit monoclonal antibody were purchased from Cell Signaling 
Technology (Danvers, MA). 4’6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
solution was from Invitrogen (Carlsbad, CA). Histopaque 1083 (Sigma-Aldrich, St Louis, 
MO) and calcein AM (Calbiochem, Germany) were prepared for monocyte isolation and 
labeling. Two different antibodies for UNC5B were purchased from Abcam (Cambridge,  
MA) and Enzo Life Sciences (Farmingdale, NY). 
 
 88 
Animals 
All animal procedures were approved by the Institutional Animal Care and Usage Committee 
at the University of California, Los Angeles (UCLA). Breeders of apoE
-/-
 mice were 
purchased from Jackson Laboratory (Bar Harbor, ME, Strain B6.129P2-Apoe
tmlUnc
/J) and 
bred in house till experimental use. Twelve- to fourteen-weeks old male animals were infused 
with or without netrin-1 (15 ng/day) a day in advance to the commencement of high fat diet 
(HFD / 42% fat; Harlan Laboratories, Madison, WI) for 16 weeks.  
 
Netrin-1 infusion using osmotic pumps 
Netrin-1 infusion was made using osmotic pumps. In order to complete 16 weeks treatment, 
osmotic pumps were replaced twice during the HFD. Two 6-week pumps and a 4-week pump 
were used (ALZET, Cupertino, CA) per animal. Animals were anesthetized with isoflurane in 
a closed chamber and moved onto surgical stage where an inhalation anesthesia mask is 
provided. While supplying 95%/5% of O2/CO2 mixed with 1.5% isoflurane, hair at lower 
posterior neck area was removed and disinfected using ethanol and iodine solusion. A small 
incision was made at this area and 6-week or 4-week osmotic pump was inserted 
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subcutaneously. 
 
Tissue collection 
After 16-week of HFD feeding, animals were weighed and sacrificed by euthanizing with 
CO2. Heparin (0.1 mL) was injected via left ventricle and left it to circulate for a minute and 
blood was collected slowly from right ventricle using 14G needle. The collected blood was 
used to analyze lipid profile. The animals were then perfused with ice-cold PBS to flush out 
remaining blood in the body. The entire lobes of liver was removed to record its weight for 
each animal. The aorta connecting the heart was excised immediately from the body and the 
connective tissue was cleaned under a surgical microscope. The upper quarter of the heart 
including the root of aorta was used for histological analysis because tricuspid/aortic root 
tends to show atherosclerotic lesion most frequently compare to the other part of aorta. Rest 
of the part of aorta including ascending aorta, aortic arch, descending aorta and iliac artery  
branch point, was harvested and opened en face for Oil Red-O staining. 
 
Plasma lipid profile measurement 
 90 
The blood collected from right ventricle was placed in a 1.5 mL centrifuge tube and 
centrifuged at 2000 rpm for 10 min. The semi-transparent plasma phase was replaced into a 
new centrifuge tube and used for each assay. Levels of cholesterol, triglyceride and 
HDL-cholesterol were measured based on colorimetric change per manufacturer’s  
instruction. The absorbance at 500 nm was detected using Bio-Tek plate reader. 
 
Oil Red-O staining on aorta dissected en face 
Three percent of oil red-O solution was prepared in 2-propanol and the reagent was heated to 
56℃for 1 hr. The oil red-O reagent was diluted to 1.8 % by mixing with water and filtered 
with a 0.22 μm syringe filter. Aorta opened en face was rinsed once with 0.5 % triton 
including PBS (PBST) and then stained with working oil red-O solution for 30 min at room 
temperature. Following the staining, aorta was washed with 2-propanol for a min and 
returned to PBST for additional wash. The aorta image was obtained under the Nikon E600  
microscope and the stained lesion area was calculated using ImageJ. 
 
Aortic root histological analysis 
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The upper quarter of heart including aortic root area was sliced and collected into 4% of 
paraformaldehyde for O/N for fixation. Tissues were displaced in 10% sucrose for at least a 
few hour prior to being embedded in paraffin for sectioning at 5 μm. The paraffin section 
slicing and H&E staining was performed using the standard protocols in the Translational 
Pathology Core Laboratory Core Facility at UCLA. The slices tissue sections were also used 
for macrophage staining using anti-CD107b (Mac 3) antibody. All of the stainings were 
performed double-blindedly. 
 
Monocyte isolation 
Monocytes were isolated from the bone marrow of 6 to 8-week old male C57BL/6 mice. 
Femur and tibia bones were harvested and cleaned, and ice-cold PBS was flushed into the 
bones using insulin syringe. Histopaque 1083 was used to separate mononuclear cells by 
centrifuging at 400 xg for exactly 30 min at room temperature. The middle opaque layer was 
carefully replaced and washed with RPMI1640. 
 
Monocyte-endothelial adhesion assay 
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Bovine aortic endothelial cells (BAECs) were cultured in M199 medium on a 96-well plate 
until more than 80% confluent. On the day of the assay, 100 ng/mL of TNFα was added to 
BAECs while harvesting monocytes from the bone marrow. The concentration of 1.0 x 10
6
 
cells/mL of isolated monocytes were labeled with calcein AM. In the meanwhile, BAECs are 
treated with or without PTIO for 30 min. After 30 min of labeling, the monocytes were 
washed twice with medium and treated with or without anti-UNC5B antibody (1 μg) to block 
UNC5B receptor from binding with netrin-1. At the same time, netrin-1 (100 ng/mL) was 
added to BAECs. Both cells underwent another 30 min of incubation. At the end of the 
incubation, the medium of BAECs were removed and washed with warm PBS once. Then 
monocytes in 100 μL PBS were overlaid on top of BAECs and co-cultured for 30 min. Cells 
were gently washed with PBS twice to remove unattached cells. The level of calcein AM 
labeled monocytes adhere to BAECs were detected by reading at excitation/emission:  
485/528 nm in a Bio-Tek fluorescence plate reader. 
 
UNC5B detection in monocytes 
In order to observe the cleavage of UNC5B in response to netrin-1 binding, monocytes were 
treated with or without netrin-1 for 30 min. After the treatment, the pellet of cells were lysed, 
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and subjected to detection of intact UNC5B and cleaved UNC5B protein levels by Western 
blotting per standard protocols using 7.5 % SDS/PAGE and nitrocellulose membranes. 
Antibody from Abcam (#ab139643/ 1:500 dilution) was used to detect intact form of UNC5B, 
whereas the antibody from Enzo Life Sciences (#ALX-804-846-C100/ 1:500 dilution) was 
applied for detection of cleaved-UNC5B. The ratio of expression levels of cleaved-/ intact- 
UNC5B was calculated. 
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3-3. Results 
Netrin-1 infusion attenuated development of atherosclerosis 
In order to create an atherosclerotic model, netrin-1 was infused one day in advance 
to HFD commencement in apoE
-/-
 mice and continued for 16 weeks for the experimental 
group (Figure 3-1A), whereas control group (CTRL) was prepared without netrin-1 infusion. 
After 16 weeks of HFD, the appearance of two groups of mice are very different. As shown 
in Figure 3-1B, the body weight increase in CTRL was extremely apparent, while Netrin-1 
group stayed unchanged. The anatomical difference was mostly seen in both fat amount and 
liver hypertrophy, which simulating patients with higher risk of atherosclerosis. Further to 
visualize atherosclerotic lesion in aortas, oil red-O staining was performed and netrin-1 
significantly decreased the occurrence of lesion formation (Figure 3-1C, D). Subsequently, 
plasma lipid profile was also examined. High levels of low-density lipoprotein cholesterol 
(LDL) and triglycerides, and a low level of high-density lipoprotein cholesterol (HDL) are 
the symbolic profile in atherosclerosis patients [12]. Figure 3-2A-C showed netrin-1 lowered 
the levels of total cholesterol and triglyceride significantly, while HDL-cholesterol remained 
to be similar. Thus, apoE
-/-
with HFD created the model of human atherosclerosis pathology, 
and netrin-1 successfully alleviated the symptoms including body fat mass, liver hypertrophy, 
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lesion formation in aortas, and blood lipid profiles. 
 
 
Figure 3-1. 
 
Figure 3-1. Netrin-1 infusion prevented body weight increase and alleviated lesion 
formation in apoE
-/- 
mice fed high fat diet. ApoE
-/-
 mice were fed with high fat diet (42% 
fat) for 16 weeks, with or without netrin-1 infusion (15 ng/day). There were significant 
differences in body weight change and liver size (A). Oil red-O staining was performed to 
observe lesion formation. As is obvious, netrin-1 significantly abrogated lesion formation  
(B&C).   
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Figure 3-2. 
 
 
Figure 3-2. Netrin-1 infusion improved plasma lipid profile in apoE
-/- 
mice fed high fat 
diet. Levels of plasma cholesterol and triglyceride were robustly decreased with netrin-1 
infusion, while there was no difference in HDL-cholesterol levels. 
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Netrin-1 infusion decreased fatty streak accumulation at aortic root 
Hypercholesterolemia induced by apoE knockout and accelerated by HFD, results 
in a formation of fatty streak. Which is known as first grossly visible lesion to be formed 
during the development of atherosclerosis[3]. Triggered by fatty streak accumulation, 
subsequent vicious cycle of pathogenesis such as fibrosis and plaque rupture follows. The 
fatty streak is most frequently seen at the root of aorta which can be identified by the unique 
structure of tricuspid valve. Therefore, we screened the aortic root of both CTRL and 
Netrin-1 infused groups (Figure 3-3). The result showed 100 % chance for CTRL to develop 
huge fatty streak. This is reasonable since apoE
-/-
 mice develop hyperlipidemia and 
atherosclerosis even with normal chow diet as they age [13]. On the other hand, there were 
only three out of seven animals (=43%) with netrin-1 infusion developed fatty streak. 
Moreover, the fatty streak lesion in netrin-1 treated animals were relatively smaller. Hence,  
netrin-1 decreased fatty streak incidence in aortic root. 
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Figure 3-3 
A 
 
 
 
 
B 
 
 
 
 
 
Figure 3-3. Netrin-1 infusion decreased accumulation of fatty streak at aortic root in 
apoE
-/-
 mice fed high fat diet. Four out of four animals (=100%) of CTRL (A), while only 
three out of seven animals (=43%) with netrin-1 infusion (B) developed fatty streak. Black 
arrows indicate fatty streaks.  
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Netrin-1 infusion prevented macrophage infiltration at the aortic root 
 Under atherosclerotic environment, circulating monocytes are retained to 
endothelium and differentiated into macrophages in the subendothelial region. The 
differentiated macrophages react with modified LDLs such as ox-LDLs to form foam cells. 
The foam cells capture various immune cells such as T-cells, dendritic cells, and mast cells 
[2]. This reaction further recruits more inflammatory cells and modified LDLs, leading the 
initiation and fatty streak phase of atherosclerotic lesions [2]. Therefore, macrophage 
accumulation can be evaluated as the earliest sign of atherogenesis by immunochemical 
staining. Figure 3-4 showed apparent difference in amount of Mac-3 (CD107) positive cell 
between control and netrin-1 infused animals. This result was consistent to the fatty streak 
formation data showed in Figure 3-3, hence, it once again confirmed alleviated development 
of atherosclerosis at the early stage, by netrin-1 treatment.  
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Figure 3-4. 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
Figure 3-4. Netrin-1 infusion reduced macrophage infiltration at the aortic root. 
Immunohisto-chemistry using anti-Mac3 (CD107) antibody was performed to visualize 
macrophage accumulation. The most intense responsive areas of aortic roots were selected 
double-blindedly. CTRL animals (A) had stronger signals compare to netrin-1 infused 
animals (B). White arrowheads indicate Mac3 positive cells. 
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Netrin-1 infusion inhibited monocyte adhesion to endothelial cells via UNC5B 
Monocytes, the major source of inflammatory response in atherosclerosis, express 
UNC5B as a dominant receptor of netrin-1 [11]. UNC5B receptor is known to be a repulsive 
receptor of netrin-1; thus we hypothesized that monocytes expressing UNC5B are repulsed 
by netrin-1 expressed in endothelial cells, contributing the alleviation of inflammatory 
response in atherosclerosis. Thus monocyte-EC adhesion assay was performed. Figure 3-5A 
showed a 23% inhibition of adhesion by treating ECs with netrin-1. However, if monocytes 
were pre-treated with UNC5B antibody to mask the receptor, netrin-1 treatment on EC had 
no effect on monocyte adhesion. Although further analysis is needed, this result suggests that 
UNC5B is mediating the anti-adhesion effect in the presence of netrin-1.  
It is also known that when netrin-1 binds to UNC5B, the intracellular death domain 
of UNC5B is cleaved and the cell expressing UNC5B proceed to apoptosis [14]. Therefore, 
the cleavage of UNC5B was detected in response to netrin-1 treatment in monocytes. The 
result showed that netrin-1 significantly increased the expression of cleaved-UNC5B (Figure 
3-5B), indicating that netrin-1 binding did increase death domain activation in monocytes.  
Hence, it is reasonable to assume that anti-inflammatory effect of netrin-1 is at least 
partially mediated by anti-attraction and pro-apoptosis of monocytes via UNC5B expression.  
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Figure 3-5. 
 
Figure 3-5. Netrin-1 infusion attenuated monocyte adhesion to endothelium via UNC5B. 
The monocytes-EC adhesion assay was performed using Calcein-AM labeling on monocytes 
(A). The result shows netrin-1 treatment on ECs inhibited monocyte adhesion, but the effect 
was reduced by UNC5B antibody pre-treatment on monocytes. (n=7, **p<0.01 vs CTRL) 
Shown in (B) is western blot analysis of monocyte in response to netrin-1 treatment. UNC5B 
cleavage level was increased in monocytes in the presence of netrin-1 (n=5, ***p<0.0001). 
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3-4. Discussion 
Atherosclerosis is considered as a chronic inflammatory disease primarily caused by 
hyperlipidemia. It has long been known that hyperlipidemia environment caused endothelial 
dysfunction shown by reduced NO
• 
bioavailability [15]. A recent study showed major 
involvement of endothelial cells in cholesterol crystal formation at the subendothelial region 
[16], suggesting the rather important contribution of ECs in plaque formation than 
inflammatory cells especially at the earlier stage of atherogenesis. Therefore, we assumed the 
protective effect of netrin-1 in ECs and EPCs mediated by NO
• 
production would alleviate 
atherosclerosis progression. Our results showed abolished weight increase and liver 
hypertrophy, and reduced lesion formation by netrin-1 infusion. The plasma lipid profile was 
also improved by netrin-1. While total cholesterol and triglyceride levels were drastically 
reduced in netrin-1 infused animals, HDL-cholesterol did not change. HDL-cholesterol 
removes unesterified cholesterol from peripheral cells and delivers to hepatic cells, known as 
reverse cholesterol transport [17][18]. Therefore it has anti-atherosclerotic, anti-inflammatory, 
and endothelial protective effect. Although our HDL-cholesterol measurement in CTRL 
animals was as high as netrin-1 infused animals, the ratio of HDL- versus total-cholesterol is 
much lower in CTRL group. Hence, the plasma lipid profiles of CTRL and netrin-1 groups  
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successfully simulated atherosclerosis and healthy subjects, respectively. 
Another important finding from our study is that netrin-1 inhibited monocyte 
adhesion to ECs, and increased UNC5B cleavage in monocytes. These results indicate that 
netrin-1 repelled monocytes from endothelium, and increased monocyte apoptosis. Although 
further studies are warranted, it may be reasonable to assume netrin-1 binding to UNC5B in 
monocyte induced cleavage of death domain of UNC5B and activated apoptosis [14]. This 
implies that netrin-1 may prevent plaque rupture, meaning that netrin-1 may be able to 
reverse the earliest stage of atherosclerosis lesion. This is consistent to our finding on reduced 
macrophage accumulation in netrin-1 infused animals. However, future study is definitely 
needed, for example, by utilizing UNC5B mutant animals to confirm an intermediate role of  
UNC5B is monocyte-dependent protective mechanisms of netrin-1 on atherogenesis.  
 In summary, our study demonstrated netrin-1’s protective effect against 
pathogenesis of atherosclerosis is at least partially mediated by recovering endothelial 
function via restored NO
• 
production and also by inhibiting monocyte activation. We believe 
this study will shed new light on netrin-1’s potential in preventive medicine. In view of the 
high prevalence of atherosclerotic cardiovascular diseases, our findings might of be high  
translational potential in promoting novel therapeutics.  
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4. Netrin-1 promotes cell cycling of endothelial cells 
 
In previous chapters, the protective effect of netrin-1 was demonstrated using in vivo models 
that simulating human vascular diseases. Those positive outcomes of protective effects were 
mediated by NO
•
 production from both endothelial cells or endothelial progenitor cells. 
Netrin-1 activate eNOS via ERK activity when it binds to DCC receptor that is dominantly 
expressed in the ECs, which promotes mitogenic activity of ECs [1]. However, the 
mechanistic details as to how netrin-1 induces endothelial cell proliferation remain unknown. 
In this chapter, we investigated the effects of netrin-1 on endothelial cell cycling and 
proliferation. The phosphorylation of PKC (pan, ser660), which is known to induce p21
waf1/cip
, 
as well as the expressionsof p27
kip1
, p21
waf1/cip
, and phosphorylation of Retinoblastoma (Rb) 
were examined for cell cycle modification made by netrin-1 treatment in ECs. 
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4-1. Introduction 
Previously, we have demonstrated that netrin-1 promotes angiogenesis in endothelial 
cells through ERK1/2 dependent NO
• 
production following DCC activation [1]. Wound 
healing orchestrated by cell proliferation and migration was accelerated by netrin-1 
treatment[1]. However, the underlying mechanisms whereby netrin-1 modulates endothelial 
cell proliferation remain unclear. The wound repair process demands complex and 
coordinated molecular signaling of endothelial cells. The cell cycle not only plays an 
important role for these signaling but also directly influences multiple cell processes,  
including DNA repair, apoptosis, cell proliferation and cell migration[2]. 
Cell cycle is tightly regulated by transcription factors, cyclins, cyclin dependent 
kinases (CDKs), and their inhibitors (CKIs). In particular, the retinoblastoma tumor 
suppressor protein (Rb) acts as the key switch in modulating the mammalian cell proliferation 
by inhibiting the transition of G1-S phase [3]. While binding of Rb to E2F family 
transcription factors suppresses their transcriptional activity, phosphorylation of Rb mediated 
by cyclin dependent kinase (CDK)-cyclin complexes causes conformational changes to 
release E2Fs. Then expressions of genes required for progression towards S phase, including 
cyclin E and cyclin D are facilitated by E2Fs[4]. In addition, Rb protein activity during the 
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cell cycle can be modulated by cyclin expression, phosphatase activity, and induction of 
cyclin-dependent kinase inhibitors (CKIs), which are members of the CIP/KIP family (p21, 
p27, and p57), and INK4 family (p15, p16, p18, and p19). Furthermore, ERK1/2 signaling is 
involved in G1-S transition cell cycle progression via different mechanisms including 
regulation of cyclin D, p27
kip1
 and p21
waf1/cip
[5]. Given the ERK1/2 activation of netrin-1 in 
endothelial cell as shown previously [1] and the role of Rb in cell cycle, netrin-1 might be 
involved in Rb mediated cell cycle regulation for endothelial angiogenesis. 
Therefore, we investigated the effect of netrin-1 on cell cycle regulation to elucidate 
the mechanisms for proliferation of endothelial cells (ECs). In this study, we found that 
netrin-1 mediates the phosphorylation of Rb, which is attributed to downregulation of p27
kip1 
and p21
waf1/cip
, and subsequently resulting in enhanced cell cycle progression of G1-S 
transition. However, all these responses were fairly mild, which implies low risk of cancer 
angiogenesis development. In conclusion, Rb dependent cell cycle regulation by netrin-1  
might contribute to its known angiogenic effect in EC mildly but significantly.  
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4-2. Methods 
Reagents 
Recombinant mouse netrin-1 was purchased from R&D Systems. Primary antibodies used for 
western blot are as follows; Rb (#9309), p-Rb (#9308), p27 Kip (#2552), p-PKC (#9371) 
were all purchased from Cell Signaling, p21 was from BD Pharmingen (#556431), beta-actin 
was from Sigma (#A2066). HRP conjugated Goat Anti-Rabbit IgG and Goat Anti-Mouse IgG  
for secondary antibodies were purchased from Bio-Rad. 
 
Cell culture and transfection 
Bovine aortic endothelial cells (BAECs, Cell systems, Kirkland, WA) of passages 4-6 were 
cultured in Media 199 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS) 
to confluence and starved in 5% FBS contained media overnight before experiments.  Some 
cells were exposed to 100 ng/ml of netrin-1 for desired time course. Proliferating BAECs at 
70-80% confluence were transfected with 25 nmol/L Rb1 siRNA (QIAGEN, #SI00007112) 
using Lipofectamine RNA iMAX (Invitrogen). Culture media was changed after 48 hrs of 
transfection and subjected to each experiment. Scrambled siRNA was transfected as control 
(indicated as CT siRNA). The transfection was confirmed by detecting both Rb and phospho- 
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Rb using western blot. 
 
Cell proliferation assay 
Cell proliferation with or without Rb siRNA transfection was assessed using cell counting 
method as indicated previously[6]. BAECs were seeded at an initial density of 1.0x10
5
 
cells/well in 24-well plates and transfected with Rb siRNA as indicated above. Culture 
medium was changed after 48 hrs of transfection and the cells were treated with or without 
netrin-1 (100 ng/ml) for additional 24 hrs. Then the cells in each well were trypsinized and 
counted using a hemocytometer. 
 
Propidium iodide staining for cell cycle analysis 
Cell cycle analysis was performed by measuring DNA content in cell using a flow cytometry 
in core facility of UCLA. Cells were starved with M199 media containing 5 % FBS for 16 
hrs and then incubated in presence or absence of 100 ng/ml of netrin-1 for additional 24 hrs. 
After treatment for 24 hrs, cells were trypsinized and 1X10
6
 cells were used for fixation with 
1 ml of chilled 70 % ethanol. The DNA from cells was subsequently stained with 1 ml of 
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hypotonic staining buffer (0.1 mg/ml of propidium iodide, 0.02 mg/ml of RNAse, 0.3 % 
Triton X-100, and 1 mg/ml sodium citrate) for 15 min at 37°C. Stained samples were used for 
flow cytometry analysis using a Becton Dickinson FACScan analytic flow cytometer (Becton  
Dickinson, Mountain View, CA).  
 
Western blot analysis for cell cycle regulating proteins 
After 24 hrs starvation (with 0.5% FBS containing media), the cells were stimulated with or 
without netrin-1 (100 ng/ml) and collected by scraping the bottom of culture dishes after 1 hr 
and 6 hrs. The cells were also pre-treated with Gö 6983 (10nmol/L, Sigma #G1918), a PKC 
inhibitor, for 30 min prior to 6 hr-netrin-1 treatment. Proteins were extracted from the 
collected cells and separated by SDS-PAGE to determine relative abundance of the cell cycle 
regulation related proteins: p21, p27, p-PKC, p-Rb. The western blot analyses were 
performed as described in previous studies[7]. The concentrations of antibodies used are as 
following: p21 (1:200), p27 (1:1000), p-PKC (1:1000), and p-Rb (1:200). Beta-actin  
(1:10000) was used as internal control.  
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4-3. Results 
Netrin-1 significantly promotes cell proliferation and G1/S transition 
Our previous data demonstrated that netrin-1 accelerates endothelial cell growth in 
aortic disc and wound closure, which reflects coordinated action of migration and 
proliferation. This angiogenic effect of netrin-1 was mediated by ERK1/2 dependent NO 
production. To elucidate the underlying mechanism of angiogenesis by netrin-1, we first 
checked whether netrin-1 is capable of promoting endothelial proliferation and cell cycle 
progression. As shown in figure 4-1A, cell proliferation was significantly increased by 
netrin-1 treatment (1.30±0.04 fold increase compared to control). Further, in order to 
examine whether the increase of proliferation is due to cell cycle progression, cell cycle was 
assessed by flow cytometry to measure cellular DNA content. As shown in figure 4-1B, 
percentage of S phase was increased in netrin-1 treated endothelial cell (7.0±0.37 vs 8.8 ± 
0.48, control vs netrin-1, respectively). Thus, the data suggests the angiogenic effect of 
netrin-1 is mediated by acceleration of cell cycle progression of the endothelial cells.   
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Figure 4-1. 
 
Figure 4-1. Netrin-1 increased cell proliferation and G1 to S phase transition in cultured 
aortic endothelial cells. Bovine aortic endothelial cells (BAECs) were treated with netrin-1 
at 100 ng/mL for 24 hrs prior to analyses. A) Cell proliferation was assessed by cell counting 
with a hemocytometer. Data indicate significant elevation of BAEC proliferation by netrin-1 
treatment (n=4, p=0.0004). B) Cell cycle was analyzed by PI staining along with flow 
cytometry (n=3, *p<0.05). 
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Netrin-1 promotion of BAEC proliferation is mediated by Rb  
Phosphorylation of Rb is the key step for cells to progress into S phase, in which 
cell undergoes chromosome duplication. Therefore, we investigated the expression level of 
phospho-Rb at 1 and 6 hr time points with or without netrin-1 treatment in BAECs. A 
significant increase of phospho-Rb was seen at the presence of netrin-1 at 6 hrs (figure 4-2A). 
In order to further confirm that netrin-1 can promote EC mitosis by modulating cell cycle 
progression, we interfered Rb expression using siRNA technique. While netrin -1 
significantly increased cell proliferation in control siRNA transfected BAECs, it was 
diminished by Rb-siRNA transfection into BAECs (figure 4-2C). The transfection efficiency 
is shown in figure 4-2B. 
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Figure 4-2. 
 
Figure 4-2. Netrin-1 induced cell proliferation is mediated by Rb phosphorylation. A) 
Phospho-Rb expression in BAEC was increased significantly at 6 hrs post-treatment with 
netrin-1 (***p<0.001, n=7-8). B), C) Cells were transfected with scrambled siRNA or Rb 
siRNA. Transfection efficiency was assessed by detecting protein expression of Rb (n=6-10, 
***p<0.0001) and phospho-Rb (n=6-10, **p<0.001) with western blot (B). Transfected cells 
were treated with or without netrin-1 for 24 hrs and cell proliferation was measured using cell 
counting method as described. (n=3, **p<0.01, ***p<0.001 vs Control of CT siRNA,  
###
p<0.001 vs Netrin-1 of CT siRNA) (C).
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Rb, p27, p21 and PKC mediates netrin-1 induced cell cycle progression  
To delineate the signaling events of cell cycle progression by netrin-1, modulations 
of phosphorylation of Rb, the key player of G1/S, were examined. As shown in figure 4-2A 
and 4-3B, phosphorylation of Rb was significantly increased by netrin-1 treatment 
(1.65±0.13 folds). The phosphorylation of Rb is controlled by CDK2. When cells are 
quiescent, accumulation of CDK inhibitors (CDKI) can be observed. In particular, p27 
inhibits the cyclin E/CDK2 complex, causing the cell cycle arrest in G1 phase[8]. In this 
study, netrin-1 treatment for 6 hr decreased the expression of p27 as shown in figure 4-3C 
(0.59 ±0.08 folds), indicating the CDK2 activation by netrin-1. The similar downregulation 
of a major CDKI p21 also was observed in netrin-1 treated cells (0.68 ±0.09 folds) as shown 
in figure 4-3D. Furthermore, the phosphorylation of PKC (pan, ser660), which is known to 
induce p21[9], was abolished by netrin-1 (0.59 ±0.08 folds) (figure 4-3E). In order to further 
confirm the involvement of PKC in the cell cycle signaling modulated by netrin-1, we 
pre-treated cells with Gö 6983 for 30 min prior to netrin-1 treatment on cells. As shown in 
figure 4-3A-E, Gö 6983 pre-treatment abolished the effect of netrin-1. These results suggest 
PKC lies up-stream of p27, p21, and Rb, facilitating netrin-1-dependent cell cyclying 
progression in BAECs. Representative images from western blot are shown in figure 4-3A.  
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Figure 4-3. 
 
 
 
 
 
Figure 4-3. Signaling cascades mediating 
netrin-1 induced cell cycling process. 
Expressions of phospho-Rb, p27, p21 and 
phospho-PKC were detected in BAECs with or without pre-treatment of PKC inhibitor Gö 
6983 (10nmol/L, 30min) and treatment of netrin-1 for 1hr or 6 hrs. A) Representative images 
of western blot. B-E) Quantified data from western blot analysis. P27, p21, and 
phospho-PKC showed significant decrease by netrin-1 treatment for 6 hrs. While phospho-Rb 
was increased by netrin-1 at 6 hrs. However, these modifications lead by netrin-1 treatment 
were abolished by Gö 6983 pre-treatment (n=7-8, p values are indicated individually).  
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4-4. Discussion 
In this study, we demonstrated that the promotion of endothelial mitogenic activity 
stimulated by netrin-1 was at least partially induced by acceleration of cell cycle progression. 
Moreover, we elucidated, for the first time, that netrin-1 reduces activation of PKC and 
further decreases p21/p27 that arrest cell cycle from entering S phase, therefore triggering Rb 
release from E2F complex to contribute to DNA replication. The schematic figure of 
signaling pathways are shown in figure 4-4. 
Netrin-1 exerted modest but statistically significant increase in proliferation and cell 
cycle progression. The marked effect of netrin-1 shown in wound closure assay [1] might be 
resulted from synergy of combined responses of migration and proliferation. It also should be 
noted that these measurements were performed in the absence of any pathological stimuli, so 
these modest responses might be markedly amplified under pathological conditions. 
Consistent with our results, other angiogenic factors such as VEGF activates Rb 
mediated cell cycle progression via p27 dependent mechanisms. Overexpression of 
caveolin-1 prevents VEGF-induced down-regulation of the p27 and Rb phosphorylation, and 
subsequently arrests endothelial cells in the G1 phase[10]. It is known that caveolin-1 inhibits 
eNOS function; so that the effect of VEGF is similar to netrin-1 in inducing cell proliferation 
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via eNOS production of NO. Taken together, netrin-1 promoted p27 downregulation and Rb 
phosphorylation would be downstream event of eNOS activation.  At least partially p53 
replaces the role of p21 dependent Rb regulation in VEGF stimulated endothelial cells. Our 
data seem to suggest netrin-1 employs both p27 and p21 to regulate Rb for cell cycle  
modulation. 
 We previously showed that there is a feed-forward activating mechanisms between 
ERK1/2 and eNOS, when netrin-1 binds to DCC in endothelial cells[1]. Moreover, PKC has 
been greatly recognized as a substrate of ERK1/2 activation [11][12][13], which in turn 
controls various biological responses including cell proliferation, differentiation, and cell 
death[14]. On the other hand, PKC also regulates p21 and p27[11], which inhibits the 
phosphorylation of Rb thus contributing to cell cycle arrest. This outcome of cell mitogen 
induced by PKC might be the answer of netrin-1’s modest effect on proliferation and  
migration of endothelial cells under a regular condition.  
In conclusion, we demonstrated for the first time that the endothelial cell proliferation 
promoted by netrin-1 is at least partially attributed to the inhibition of cell cycle arrest 
through activation of Rb,. Moreover, we also identified that PKC lies upstream of p21/p27 
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regulating Rb activation in the aortic endothelial cells. Further investigations are required to 
address the physiological significance of PKC and Rb in mediating netrin-1’s effects on  
endothelial cell signaling.   
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Figure 4-4. 
 
Figure 4-4. Schematic illustration of mechanistic insights underlying netrin-1 induced 
cell cycling progress. Netrin-1 inhibits PKC activation in BAECs, leading to subsequent 
inhibition of CDK4/6 inhibitor p21/p27; and this would result in increased Rb 
phosphorylation to promote cell cycling. Thus netrin-1 accelerates G1/S transition of the  
cells. Red arrows indicate expression modifications by netrin -1 treatment. 
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5. Conclusion 
 
The present study demonstrates a robust vascular protective effect of netrin-1 and 
netrin-1 preconditioned EPCs using two vascular disease models of femoral artery wire 
injury for neointimal formation and apoE knockout mice fed high fat diet for atherosclerosis.  
We have previously discovered that the axon guiding molecular netrin-1 exerts angiogenic 
effect via DCC receptor dependent production of NO
• 
from endothelial cells. Since NO
• 
bioavailability is the most important factor to maintain vascular homeostasis, we proceeded 
to examine the potential protective effects of netrin-1 in vascular disease models. 
Femoral artery wire injury was employed as a pathological model for neointimal 
growth following endothelial injury. Since VSMCs are the major component in growing 
neointima, we created a co-culture system of EC and VSMC to examine netrin-1’s effect on 
VSMC migration and proliferation. The experiments identified a novel signaling pathway of 
NO
•
/cGMP/p38 MAPK in mediating attenuation of VSMC migration and proliferation. We 
confirmed elevated levels of bioavailable NO
•
 in injured femoral arteries by electron spin 
resonance (ESR), indicating that netrin-1 was able to increase NO
•
 production in remaining 
endothelial cells. Our further data indicate that netrin-1 was able to increase NO
•
 production 
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in netrin-1 preconditioned EPCs as well, which is required to enhance EPC-dependent 
revascularization to accelerate vascular repair. The proliferative activity and resistance to 
oxidative stress induced apoptosis of EPCs are both improved in response to netrin-1 
preconditioning.  These beneficial effects of netrin-1 treatment are highly significant as the 
challenges in clinical therapy using EPCs are the sparseness and the vulnerability. In 
additional experiments, EPCs pre-conditioned with netrin-1 were injected in vivo in the 
femoral artery wire injury model, where we observed robust vascular protection using much 
less number of cells at only 500. 
 In the atherosclerotic model of high fat fed apoE knockout mice, we observed 
improved phenotypes by netrin-1 infusion, as reflected by reductions in body weight and 
liver enlargement, improvement in plasma lipid profile, as well as reductions in lesion 
formation and macrophage infiltration. Monocytes were also examined in this model since 
they are an indispensable cell type in inflammatory-driven pathology triggered by damaged 
ECs. We found that netrin-1 inhibited monocyte adhesion to ECs and this effect was 
abolished in the absence of UNC5B receptor. It suggests that netrin-1 repulsed monocyte 
adhesion to endothelium via UNC5B and thus decreased macrophage accumulation. 
 In the last chapter, we examined the cell cycling effect of netrin-1 on ECs, and PKC 
130 
 
and Rb were implicated in the increased proliferation as cell cycling progresses. Although the 
netrin-1 regulation of PKC/Rb axis was relatively modest, it may however indicate the 
modest change prevents netrin-1 to have a profound impact on cancer angiogenesis. 
 Overall, the present study for the first time demonstrates robust vascular protective 
effects of netrin-1 and netrin-1 pre-conditioned EPCs that are mediated by DCC-dependent 
increase in NO
•
 production, NO
•
-mediated inhibition of VSMC migration and proliferation, 
NO
•
-mediated improvements in EPC functions by netrin-1 preconditioning, and UBC5B 
mediated attenuation of monocyte adhesion to ECs. These data indicate that both netrin-1 and 
netrin-1 pre-conditioned EPCs may serve as novel therapeutic options for the treatment of 
vascular diseases. 
 
